<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="23f68487-5d22-4618-9ccc-417aeb9fd3a8"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use DUETACT<sup>®</sup> safely and effectively. See full prescribing information for DUETACT.<br/>DUETACT (pioglitazone and glimepiride) tablets for oral use<br/>Initial U.S. Approval: 2006</title>
   <effectiveTime value="20250327"/>
   <setId root="f8b0c917-3fdd-4a28-a47d-6225b8195458"/>
   <versionNumber value="23"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="039997266" root="1.3.6.1.4.1.519.1"/>
            <name>Takeda Pharmaceuticals America, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="313270015" root="1.3.6.1.4.1.519.1"/>
                        <name> Takeda GmbH </name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64764-302" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64764-304" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64764-302" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64764-304" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64764-302" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64764-304" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="390e35c5-eaad-4733-a3f4-205afbd529d8"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250327"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="64764-302" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Duetact</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>pioglitazone and glimepiride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="30"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JQT35NPK6C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>pioglitazone hydrochloride</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="X4OV71U42S" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>pioglitazone</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="2"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6KY687524K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>glimepiride</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="6KY687524K" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>glimepiride</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>croscarmellose sodium</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>lactose monohydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>magnesium stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RFW2ET671P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (1600000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>polysorbate 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>microcrystalline cellulose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="64764-302-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20060728"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="90"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="64764-302-90" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20060728"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA021925" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20060728"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>white to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="8" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText>convex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">30;2;4833G</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="64764-304" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Duetact</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>pioglitazone and glimepiride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="30"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JQT35NPK6C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>pioglitazone hydrochloride</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="X4OV71U42S" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>pioglitazone</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="4"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6KY687524K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>glimepiride</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="6KY687524K" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>glimepiride</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>croscarmellose sodium</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>lactose monohydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>magnesium stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RFW2ET671P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (1600000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>polysorbate 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>microcrystalline cellulose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="64764-304-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20060728"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="90"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="64764-304-90" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20060728"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA021925" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20060728"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>white to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText>convex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">30;4;4833G</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_0c4793ce-1fea-4a33-925c-20a3289996b7">
               <id root="36a848ba-71dc-43d6-bf9a-67fad3856dd4"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="Boxed Warning section"/>
               <title>WARNING: CONGESTIVE HEART FAILURE</title>
               <text>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>
                        <content styleCode="Bold">Thiazolidinediones, including pioglitazone, which is a component of DUETACT<sup>®</sup>, cause or exacerbate congestive heart failure in some patients <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_43d57886-ef7e-432b-98da-4da298165ad3">5.1</linkHtml>)]</content>.</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="Bold">After initiation of DUETACT and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of DUETACT must be considered <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_43d57886-ef7e-432b-98da-4da298165ad3">5.1</linkHtml>)]</content>.</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="Bold">DUETACT is not recommended in patients with symptomatic heart failure <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_43d57886-ef7e-432b-98da-4da298165ad3">5.1</linkHtml>)]</content>.</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="Bold">Initiation of DUETACT in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated <content styleCode="italics">[see Contraindications (<linkHtml href="#ID_9a86b0c1-3462-4c7f-965d-bc1f7cb90fa3">4</linkHtml>) </content>and <content styleCode="italics">Warnings and Precautions (<linkHtml href="#ID_43d57886-ef7e-432b-98da-4da298165ad3">5.1</linkHtml>)]</content>.</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: CONGESTIVE HEART FAILURE</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="Bold">Thiazolidinediones, including pioglitazone, which is a component of DUETACT, cause or exacerbate congestive heart failure in some patients. (<linkHtml href="#ID_43d57886-ef7e-432b-98da-4da298165ad3">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="Bold">After initiation of DUETACT, and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of DUETACT must be considered. (<linkHtml href="#ID_43d57886-ef7e-432b-98da-4da298165ad3">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="Bold">DUETACT is not recommended in patients with symptomatic heart failure. (<linkHtml href="#ID_43d57886-ef7e-432b-98da-4da298165ad3">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="Bold">Initiation of DUETACT in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated. (<linkHtml href="#ID_9a86b0c1-3462-4c7f-965d-bc1f7cb90fa3">4</linkHtml>, <linkHtml href="#ID_43d57886-ef7e-432b-98da-4da298165ad3">5.1</linkHtml>)</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_b73995ea-d331-48ed-b317-4185308c70b5">
               <id root="17dc5935-d545-4f76-a1ee-b621f5c4280a"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>DUETACT is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and sulfonylurea or who have inadequate glycemic control on a thiazolidinedione alone or a sulfonylurea alone <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID_b4aef75b-fea1-430c-9047-d11c7e9f2955">14</linkHtml>)]</content>. 						</paragraph>
                  <paragraph>
                     <content styleCode="bold">Important Limitations of Use</content>
                  </paragraph>
                  <paragraph>Pioglitazone exerts its antihyperglycemic effect only in the presence of endogenous insulin. DUETACT should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings.</paragraph>
                  <paragraph>Use caution in patients with liver disease <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_53794fa4-8315-403d-bb0f-afe3fa0643e8">5.5</linkHtml>)]</content>. 						</paragraph>
               </text>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>DUETACT is a thiazolidinedione and a sulfonylurea combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both pioglitazone and glimepiride is appropriate. (<linkHtml href="#ID_b73995ea-d331-48ed-b317-4185308c70b5">1</linkHtml>)</paragraph>
                        <paragraph> </paragraph>
                        <paragraph>Important Limitations of Use:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Not for treatment of type 1 diabetes or diabetic ketoacidosis. (<linkHtml href="#ID_b73995ea-d331-48ed-b317-4185308c70b5">1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_6eb7db91-4594-4e9e-b287-41d9ecb8b998">
               <id root="c4a51303-a7a4-4c60-8b65-5b6ba6ee5032"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Individualize the starting dose of DUETACT based on the patient's current regimen. (<linkHtml href="#ID_d5a3f4e6-30f8-450a-a20d-99631baa2b7e">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>May adjust the dosing based on effectiveness and tolerability while not exceeding the maximum recommended daily dose of pioglitazone 45 mg and glimepiride 8 mg. (<linkHtml href="#ID_d5a3f4e6-30f8-450a-a20d-99631baa2b7e">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>DUETACT should be given in a single dose once daily with meals. (<linkHtml href="#ID_d5a3f4e6-30f8-450a-a20d-99631baa2b7e">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Obtain liver tests before starting DUETACT. If abnormal, use caution when treating with DUETACT, investigate the probable cause, treat (if possible) and follow appropriately. Monitoring liver tests while on DUETACT is not recommended in patients without liver disease. (<linkHtml href="#ID_53794fa4-8315-403d-bb0f-afe3fa0643e8">5.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_d5a3f4e6-30f8-450a-a20d-99631baa2b7e">
                     <id root="f4afaa12-30ba-4592-8cd1-4130847ce903"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommendations for All Patients</title>
                     <text>
                        <paragraph>DUETACT should be taken once daily with the first main meal.</paragraph>
                        <paragraph>DUETACT tablets are available as a 30 mg pioglitazone plus 2 mg glimepiride or a 30 mg pioglitazone plus 4 mg glimepiride tablet. If therapy with a combination tablet containing pioglitazone and glimepiride is considered appropriate the recommended starting dose is:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>30 mg/2 mg or 30 mg/4 mg once daily and gradually titrated, as needed, after assessing adequacy of therapeutic response and tolerability,</item>
                           <item>
                              <caption>•</caption>for patients inadequately controlled on glimepiride monotherapy: 30 mg/2 mg or 30 mg/4 mg once daily and gradually titrated, as needed, after assessing adequacy of therapeutic response and tolerability,</item>
                           <item>
                              <caption>•</caption>for patients inadequately controlled on pioglitazone monotherapy: 30 mg/2 mg once daily and gradually titrated, as needed, after assessing adequacy of therapeutic response and tolerability,</item>
                           <item>
                              <caption>•</caption>for patients who are changing from combination therapy of pioglitazone plus glimepiride as separate tablets: DUETACT should be taken at doses that are as close as possible to the dose of pioglitazone and glimepiride already being taken,</item>
                           <item>
                              <caption>•</caption>for patients currently on a different sulfonylurea monotherapy or switching from combination therapy of pioglitazone plus a different sulfonylurea (e.g., glyburide, glipizide, chlorpropamide, tolbutamide, acetohexamide): 30 mg/2 mg once daily and adjusted after assessing adequacy of therapeutic response. Observe for hypoglycemia for one to two weeks due to the potential overlapping drug effect.</item>
                           <item>
                              <caption>•</caption>for patients with systolic dysfunction, the lowest approved dose of DUETACT should be prescribed only after titration from 15 mg to 30 mg of pioglitazone has been safely tolerated.</item>
                        </list>
                        <paragraph>After initiation of DUETACT or with dose increase, monitor patients carefully for hypoglycemia and adverse reactions related to fluid retention such as weight gain, edema, and signs and symptoms of congestive heart failure <content styleCode="italics">[see Boxed Warning</content> and <content styleCode="italics">Warnings and Precautions (<linkHtml href="#ID_a900dc5c-aedc-4c59-baa6-fbe467ed26f2">5.7</linkHtml>)]</content>. 								</paragraph>
                        <paragraph>Liver tests (serum alanine and aspartate aminotransferases, alkaline phosphatase, and total bilirubin) should be obtained prior to initiating DUETACT. Routine periodic monitoring of liver tests during treatment with DUETACT is not recommended in patients without liver disease. Patients who have liver test abnormalities prior to initiation of DUETACT or who are found to have abnormal liver tests while taking DUETACT should be managed as described under Warnings and Precautions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_53794fa4-8315-403d-bb0f-afe3fa0643e8">5.5</linkHtml>)</content> and <content styleCode="italics">Clinical Pharmacology (<linkHtml href="#ID_07099e0b-57b6-4d9f-9ef0-996ecac15370">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_902ce5dc-e1cd-4651-9130-8c302e78c093">
                     <id root="1a1bcf75-60d5-4bd3-91c9-87338b01fd5a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Concomitant Use with an Insulin Secretagogue or Insulin</title>
                     <text>
                        <paragraph>If hypoglycemia occurs in a patient coadministered DUETACT and an insulin secretagogue, the dose of the insulin secretagogue should be reduced.</paragraph>
                        <paragraph>If hypoglycemia occurs in a patient coadministered DUETACT and insulin, the dose of insulin should be decreased by 10% to 25%. Further adjustments to the insulin dose should be individualized based on glycemic response.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2ab15827-baf8-4e8b-8663-a03eab934860">
                     <id root="c31021e0-3278-43b4-b25b-9b919bea71c8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Concomitant Use with Strong CYP2C8 Inhibitors</title>
                     <text>
                        <paragraph>Coadministration of pioglitazone and gemfibrozil, a strong CYP2C8 inhibitor, increases pioglitazone exposure approximately 3-fold. Therefore, the maximum recommended dose of pioglitazone is 15 mg daily when used in combination with gemfibrozil or other strong CYP2C8 inhibitors. If gemfibrozil or other CYP2C8 inhibitors need to co-administered, patients should switch to individual components of DUETACT because the minimum dose of pioglitazone in DUETACT exceeds 15 mg <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_26d9e3b6-d7a9-4bf4-8120-875349f081f2">7.1</linkHtml>) </content>and <content styleCode="italics">Clinical Pharmacology (<linkHtml href="#ID_07099e0b-57b6-4d9f-9ef0-996ecac15370">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_516f2365-8931-476a-98aa-624650f5af10">
                     <id root="073c9669-e8fe-4e74-8463-be916b420c28"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Concomitant Use with Colesevelam</title>
                     <text>
                        <paragraph>When colesevelam is coadministered with glimepiride, maximum plasma concentration and total exposure to glimepiride is reduced. Therefore, DUETACT should be administered at least four hours prior to colesevelam <content styleCode="italics">[see Drug Interactions (<linkHtml href="#S7.7">7.7</linkHtml>)</content> and <content styleCode="italics">Clinical Pharmacology (<linkHtml href="#ID_07099e0b-57b6-4d9f-9ef0-996ecac15370">12.3</linkHtml>)]</content>. 								</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_d8ee0aff-4d75-42c5-96a3-2f6ef30d64a1">
               <id root="3d0ce04f-745c-425e-ac2b-6c4b365f701e"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>30 mg/2 mg tablet: White to off-white, round, convex tablets, debossed with "4833G" on one side and "30/2" on the other</item>
                     <item>
                        <caption>•</caption>30 mg/4 mg tablet: White to off-white, round, convex tablets, debossed with "4833G" on one side and "30/4" on the other</item>
                  </list>
               </text>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Tablets: 30 mg pioglitazone/2 mg glimepiride. (<linkHtml href="#ID_d8ee0aff-4d75-42c5-96a3-2f6ef30d64a1">3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Tablets: 30 mg pioglitazone/4 mg glimepiride. (<linkHtml href="#ID_d8ee0aff-4d75-42c5-96a3-2f6ef30d64a1">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_9a86b0c1-3462-4c7f-965d-bc1f7cb90fa3">
               <id root="8e811bea-dce3-4df8-8c8c-4027f602ef20"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Initiation in patients with established NYHA Class III or IV heart failure <content styleCode="italics">[see <linkHtml href="#ID_0c4793ce-1fea-4a33-925c-20a3289996b7">Boxed Warning</linkHtml>]</content>. 							</item>
                     <item>
                        <caption>•</caption>Use in patients with known hypersensitivity to pioglitazone, glimepiride or any other component of DUETACT <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_663ce6b7-5b98-4c22-b86c-1a44498ebf81">5.3</linkHtml>)]</content>. 							</item>
                     <item>
                        <caption>•</caption>Use in patients with known history of an allergic reaction to sulfonamide derivatives.</item>
                  </list>
                  <paragraph>							Reported hypersensitivity reactions with glimepiride include cutaneous eruptions with or without pruritus as well as more serious reactions (e.g., anaphylaxis, angioedema, Stevens-Johnson Syndrome, dyspnea) <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#ID_663ce6b7-5b98-4c22-b86c-1a44498ebf81">5.3</linkHtml>) and Adverse Reactions (<linkHtml href="#ID_bad75148-3d9e-416a-8df9-a335906706ba">6.2</linkHtml>)]</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Initiation in patients with established New York Heart Association (NYHA) Class III or IV heart failure <content styleCode="italics">[see <linkHtml href="#ID_0c4793ce-1fea-4a33-925c-20a3289996b7">Boxed Warning</linkHtml>]</content>. (<linkHtml href="#ID_9a86b0c1-3462-4c7f-965d-bc1f7cb90fa3">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Use in patients with known hypersensitivity to pioglitazone, glimepiride or any other component of DUETACT. (<linkHtml href="#ID_9a86b0c1-3462-4c7f-965d-bc1f7cb90fa3">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Hypersensitivity to sulfonamide derivatives. (<linkHtml href="#ID_9a86b0c1-3462-4c7f-965d-bc1f7cb90fa3">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_8056d4f9-090a-4dc3-8de0-06e54b4e9098">
               <id root="8092b812-f816-4c1e-b386-d3a05ce822ce"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Congestive heart failure: Fluid retention may occur and can exacerbate or lead to congestive heart failure. Combination use with insulin and use in congestive heart failure NYHA Class I and II may increase risk. Monitor patients for signs and symptoms. (<linkHtml href="#ID_43d57886-ef7e-432b-98da-4da298165ad3">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Hypoglycemia: May be severe. When insulin or an insulin secretagogue is used with pioglitazone, a lower dose of the insulin or insulin secretagogue may be needed to reduce the risk of hypoglycemia. (<linkHtml href="#ID_54fc55ff-dfa7-48fa-8b7b-4af50e1bc0c5">5.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Hypersensitivity Reactions: Postmarketing reports for glimepiride, a component of DUETACT, include anaphylaxis, angioedema and Stevens-Johnson Syndrome. Promptly discontinue DUETACT, assess for other cases, institute appropriate monitoring and treatment, and initiate alternative treatment for diabetes. (<linkHtml href="#ID_663ce6b7-5b98-4c22-b86c-1a44498ebf81">5.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Potential increased risk of cardiovascular mortality with sulfonylureas: Inform patients of risk, benefits, and treatment alternatives. (<linkHtml href="#ID_c4b2beb4-d634-4948-8320-98d34c41ecd8">5.4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal. Causality cannot be excluded. If liver injury is detected, promptly interrupt DUETACT and assess patient for probable cause, then treat cause if possible, to resolution or stabilization. Do not restart DUETACT if liver injury is confirmed and no alternate etiology can be found. (<linkHtml href="#ID_53794fa4-8315-403d-bb0f-afe3fa0643e8">5.5</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Bladder cancer: May increase the risk of bladder cancer. Do not use in patients with active bladder cancer. Use caution when using in patients with a prior history of bladder cancer (<linkHtml href="#ID_2db7c10b-65e8-4bf1-b77a-50013093b448">5.6</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Edema: Dose-related edema may occur. (<linkHtml href="#ID_a900dc5c-aedc-4c59-baa6-fbe467ed26f2">5.7</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Fractures: Increased incidence in female patients. Apply current standards of care for assessing and maintaining bone health. (<linkHtml href="#ID_ba6afe77-f86c-4e04-aca1-34cae25dc8d7">5.8</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Hemolytic anemia: Can occur if glucose 6-phophate dehydrogenase (GP6D) deficient. Use with caution in patients with GP6D deficiency. (<linkHtml href="#ID_68dff23d-b99b-4dad-9f12-a6f434544f59">5.9</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Macular edema: Postmarketing reports. Recommend regular eye exams in all patients with diabetes according to current standards of care with prompt evaluation for acute visual changes. (<linkHtml href="#ID_689c304b-df44-4f4e-88f1-bba619e6272e">5.10</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Macrovascular outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with DUETACT. (<linkHtml href="#ID_767da48d-455a-4cce-8526-d91825c95836">5.11</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_43d57886-ef7e-432b-98da-4da298165ad3">
                     <id root="574ddf74-2cf7-4bf3-86c0-f84d07edbacd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Congestive Heart Failure</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Pioglitazone</content>
                        </paragraph>
                        <paragraph>Pioglitazone, like other thiazolidinediones, can cause dose-related fluid retention when used alone or in combination with other antidiabetic medications and is most common when DUETACT is used in combination with insulin. Fluid retention may lead to or exacerbate congestive heart failure. Patients should be observed for signs and symptoms of congestive heart failure. If congestive heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of DUETACT must be considered <content styleCode="italics">[see Boxed Warning, Contraindications (<linkHtml href="#ID_9a86b0c1-3462-4c7f-965d-bc1f7cb90fa3">4</linkHtml>) and Adverse Reactions (<linkHtml href="#ID_403e192e-afdf-4ae3-9f8c-8e1b6c5129cc">6.1</linkHtml>)]</content>. 								</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_54fc55ff-dfa7-48fa-8b7b-4af50e1bc0c5">
                     <id root="bf763152-f0d8-403b-86e8-3ac3762b9569"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Hypoglycemia</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Glimepiride</content>
                        </paragraph>
                        <paragraph>All sulfonylureas, including glimepiride, a component of DUETACT, can cause severe hypoglycemia <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID_403e192e-afdf-4ae3-9f8c-8e1b6c5129cc">6.1</linkHtml>)]</content>. The patient's ability to concentrate and react may be impaired as a result of hypoglycemia. These impairments may present a risk in situations where these abilities are especially important, such as driving or operating other machinery. Severe hypoglycemia can lead to unconsciousness or convulsions and may result in temporary or permanent impairment of brain function or death.</paragraph>
                        <paragraph>Patients must be educated to recognize and manage hypoglycemia. Use caution when initiating and increasing DUETACT doses in patients who may be predisposed to hypoglycemia (e.g., the elderly, patients with renal impairment, patients on other antidiabetic medications). Debilitated or malnourished patients and those with adrenal, pituitary, or hepatic impairment are particularly susceptible to the hypoglycemic action of glucose-lowering medications. Hypoglycemia is also more likely to occur when caloric intake is deficient, after severe or prolonged exercise, or when alcohol is ingested.</paragraph>
                        <paragraph>Early warning symptoms of hypoglycemia may be different or less pronounced in patients with autonomic neuropathy, the elderly, and in patients who are taking beta-adrenergic blocking medications or other sympatholytic agents. These situations may result in severe hypoglycemia before the patient is aware of the hypoglycemia.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_663ce6b7-5b98-4c22-b86c-1a44498ebf81">
                     <id root="0d8a0811-822e-430d-ac72-6a3a2b0b0c17"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Glimepiride</content>
                        </paragraph>
                        <paragraph>There have been postmarketing reports of hypersensitivity reactions in patients treated with glimepiride, a component of DUETACT, including serious reactions such as anaphylaxis, angioedema, and Stevens-Johnson Syndrome. If a hypersensitivity reaction is suspected, promptly discontinue DUETACT, assess for other potential causes for the reaction, and institute alternative treatment for diabetes.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c4b2beb4-d634-4948-8320-98d34c41ecd8">
                     <id root="9dfc57ab-1b36-4e73-96bf-56dac702c905"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Potential Increased Risk of Cardiovascular Mortality with Sulfonylureas</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Glimepiride</content>
                        </paragraph>
                        <paragraph>The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term, prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups.</paragraph>
                        <paragraph>UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2.5 times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of glimepiride tablets and of alternative modes of therapy.</paragraph>
                        <paragraph>Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_53794fa4-8315-403d-bb0f-afe3fa0643e8">
                     <id root="d83ef6c1-b663-4c8b-bdf8-7323edf6528d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Hepatic Effects</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Pioglitazone</content>
                        </paragraph>
                        <paragraph>There have been postmarketing reports of fatal and non-fatal hepatic failure in patients taking pioglitazone, although the reports contain insufficient information necessary to establish the probable cause. There has been no evidence of drug-induced hepatotoxicity in the pioglitazone-controlled clinical trial database to date <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID_403e192e-afdf-4ae3-9f8c-8e1b6c5129cc">6.1</linkHtml>)]</content>. 								</paragraph>
                        <paragraph>Patients with type 2 diabetes may have fatty liver disease or cardiac disease with episodic congestive heart failure, both of which may cause liver test abnormalities, and they may also have other forms of liver disease, many of which can be treated or managed. Therefore, obtaining a liver test panel (serum alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase, and total bilirubin) and assessing the patient is recommended before initiating DUETACT therapy. In patients with abnormal liver tests, DUETACT should be initiated with caution.</paragraph>
                        <paragraph>Measure liver tests promptly in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice. In this clinical context, if the patient is found to have abnormal liver tests (ALT greater than 3 times the upper limit of the reference range), DUETACT treatment should be interrupted and investigation done to establish the probable cause. DUETACT should not be restarted in these patients without another explanation for the liver test abnormalities.</paragraph>
                        <paragraph>Patients who have serum ALT greater than three times the reference range with serum total bilirubin greater than two times the reference range without alternative etiologies are at risk for severe drug-induced liver injury and should not be restarted on DUETACT. For patients with lesser elevations of serum ALT or bilirubin and with an alternate probable cause, treatment with DUETACT can be used with caution.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2db7c10b-65e8-4bf1-b77a-50013093b448">
                     <id root="232a41af-5e1c-42f4-a663-f174add5a0cc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Urinary Bladder Tumors</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Pioglitazone</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Tumors were observed in the urinary bladder of male rats in the two-year carcinogenicity study <content styleCode="italics">[see Nonclinical Toxicology <linkHtml href="#ID_940c289c-9f6e-455c-a221-e290f34bd3a4">(13.1)</linkHtml>].</content> In addition, during the three year PROactive clinical trial, 14 patients out of 2605 (0.54%) randomized to pioglitazone and 5 out of 2633 (0.19%) randomized to placebo were diagnosed with bladder cancer. After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of bladder cancer, there were 6 (0.23%) cases on pioglitazone and two (0.08%) cases on placebo. After completion of the trial, a large subset of patients was observed for up to 10 additional years, with little additional exposure to pioglitazone. During the 13 years of both PROactive and observational follow-up, the occurrence of bladder cancer did not differ between patients randomized to pioglitazone or placebo (HR =1.00; [95% CI: 0.59–1.72]).</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Findings regarding the risk of bladder cancer in patients exposed to pioglitazone vary among observational studies; some did not find an increased risk of bladder cancer associated with pioglitazone, while others did.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">A large prospective 10-year observational cohort study conducted in the United States found no statistically significant increase in the risk of bladder cancer in diabetic patients ever exposed to pioglitazone, compared to those never exposed to pioglitazone (HR =1.06 [95% CI 0.89–1.26]).</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">A retrospective cohort study conducted with data from the United Kingdom found a statistically significant association between ever exposure to pioglitazone and bladder cancer (HR: 1.63; [95% CI: 1.22–2.19]).</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Associations between cumulative dose or cumulative duration of exposure to pioglitazone and bladder cancer were not detected in some studies including the 10-year observational study in the U.S., but were in others. Inconsistent findings and limitations inherent in these and other studies preclude conclusive interpretations of the observational data.</content>
                        </paragraph>
                        <paragraph>Pioglitazone may be associated with an increase in the risk of urinary bladder tumors. There are insufficient data to determine whether pioglitazone is a tumor promoter for urinary bladder tumors.</paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Consequently, DUETACT should not be used in patients with active bladder cancer and the benefits of glycemic control versus unknown risks for cancer recurrence with DUETACT should be considered in patients with a prior history of bladder cancer.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a900dc5c-aedc-4c59-baa6-fbe467ed26f2">
                     <id root="b46d348a-c2ef-4df5-840f-a701ff6a8f28"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Edema</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Pioglitazone</content>
                        </paragraph>
                        <paragraph>In controlled clinical trials, edema was reported more frequently in patients treated with pioglitazone than in placebo-treated patients and is dose-related <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID_403e192e-afdf-4ae3-9f8c-8e1b6c5129cc">6.1</linkHtml>)]</content>. In postmarketing experience, reports of new onset or worsening edema have been received.</paragraph>
                        <paragraph>DUETACT should be used with caution in patients with edema. Because thiazolidinediones, including pioglitazone, can cause fluid retention, which can exacerbate or lead to congestive heart failure, DUETACT should be used with caution in patients at risk for congestive heart failure. Patients treated with DUETACT should be monitored for signs and symptoms of congestive heart failure <content styleCode="italics">[see Boxed Warning, Warnings and Precautions (<linkHtml href="#ID_43d57886-ef7e-432b-98da-4da298165ad3">5.1</linkHtml>), and Patient Counseling Information (<linkHtml href="#ID_418a0bfd-af83-4e14-b882-af967ecd95d4">17</linkHtml>)]</content>. 								</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_ba6afe77-f86c-4e04-aca1-34cae25dc8d7">
                     <id root="57a3e8f3-65b7-45f9-88cb-0c6de863e911"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Fractures</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Pioglitazone</content>
                        </paragraph>
                        <paragraph>In PROactive (the Prospective Pioglitazone Clinical Trial in Macrovascular Events), 5238 patients with type 2 diabetes and a history of macrovascular disease were randomized to pioglitazone (N=2605), force-titrated up to 45 mg daily or placebo (N=2633) in addition to standard of care. During a mean follow-up of 34.5 months, the incidence of bone fracture in females was 5.1% (44/870) for pioglitazone versus 2.5% (23/905) for placebo. This difference was noted after the first year of treatment and persisted during the course of the study. The majority of fractures observed in female patients were nonvertebral fractures including lower limb and distal upper limb. No increase in the incidence of fracture was observed in men treated with pioglitazone (1.7%) versus placebo (2.1%). The risk of fracture should be considered in the care of patients, especially female patients, treated with DUETACT and attention should be given to assessing and maintaining bone health according to current standards of care.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_68dff23d-b99b-4dad-9f12-a6f434544f59">
                     <id root="be9e7f92-641d-4633-92bf-92d269751e37"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Hemolytic Anemia</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Glimepiride</content>
                        </paragraph>
                        <paragraph>Sulfonylureas can cause hemolytic anemia in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency. Because DUETACT contains glimepiride, which belongs to the class of sulfonylurea agents, use caution in patients with G6PD deficiency and consider the use of a nonsulfonylurea alternative. There are also postmarketing reports of hemolytic anemia in patients receiving glimepiride who did not have known G6PD deficiency <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID_bad75148-3d9e-416a-8df9-a335906706ba">6.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_689c304b-df44-4f4e-88f1-bba619e6272e">
                     <id root="b9d15b52-9b2c-43b6-81e3-7b3df2ad95e6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Macular Edema</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Pioglitazone</content>
                        </paragraph>
                        <paragraph>Macular edema has been reported in postmarketing experience in diabetic patients who were taking pioglitazone or another thiazolidinedione. Some patients presented with blurred vision or decreased visual acuity, but others were diagnosed on routine ophthalmologic examination.</paragraph>
                        <paragraph>Most patients had peripheral edema at the time macular edema was diagnosed. Some patients had improvement in their macular edema after discontinuation of the thiazolidinedione.</paragraph>
                        <paragraph>Patients with diabetes should have regular eye exams by an ophthalmologist according to current standards of care. Patients with diabetes who report any visual symptoms should be promptly referred to an ophthalmologist, regardless of the patient's underlying medications or other physical findings <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID_403e192e-afdf-4ae3-9f8c-8e1b6c5129cc">6.1</linkHtml>)]</content>. 								</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_767da48d-455a-4cce-8526-d91825c95836">
                     <id root="0f18d2d3-c70d-4485-b005-c3b0c62648ad"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11 Macrovascular Outcomes</title>
                     <text>
                        <paragraph>There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with DUETACT.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3447b8bf-b195-48cc-89d1-98c43f95b168">
               <id root="a0351b41-6e9a-4121-8116-e5d46b548353"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious adverse reactions are discussed elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Congestive Heart Failure <content styleCode="italics">[see Boxed Warning and Warnings and Precautions (<linkHtml href="#ID_43d57886-ef7e-432b-98da-4da298165ad3">5.1</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Hypoglycemia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_54fc55ff-dfa7-48fa-8b7b-4af50e1bc0c5">5.2</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Edema <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_a900dc5c-aedc-4c59-baa6-fbe467ed26f2">5.7</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Fractures <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_ba6afe77-f86c-4e04-aca1-34cae25dc8d7">5.8</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Hemolytic Anemia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_68dff23d-b99b-4dad-9f12-a6f434544f59">5.9</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (≥5%) are upper respiratory tract infection, accidental injury, and combined edema/peripheral edema. (<linkHtml href="#ID_403e192e-afdf-4ae3-9f8c-8e1b6c5129cc">6.1</linkHtml>)</paragraph>
                        <paragraph> </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals America, Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or 									<linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_403e192e-afdf-4ae3-9f8c-8e1b6c5129cc">
                     <id root="56eb7dd3-a4d8-4fdc-b424-f7aeefe2187d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The adverse events reported in at least 5% of patients in the controlled 16-week clinical studies between placebo plus a sulfonylurea and pioglitazone (15 mg and 30 mg combined) plus sulfonylurea treatment arms were upper respiratory tract infection (15.5% and 16.6%), accidental injury (8.6% and 3.5%), and combined edema/peripheral edema (2.1% and 7.2%), respectively.</paragraph>
                        <paragraph>The incidence and type of adverse events reported in at least 5% of patients in any combined treatment group from the 24-week study comparing pioglitazone 30 mg plus a sulfonylurea and pioglitazone 45 mg plus a sulfonylurea are shown in <content styleCode="italics">Table 1</content>; the rate of adverse events resulting in study discontinuation between the two treatment groups was 6% and 9.7%, respectively.</paragraph>
                        <table width="100%">
                           <col width="45%"/>
                           <col width="28%"/>
                           <col width="28%"/>
                           <tbody>
                              <tr>
                                 <td colspan="3" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Table 1. Adverse Events that Occurred in ≥5% of Patients in Any Treatment Group During the 24-Week Study</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Event</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone 30 mg</content>
                                       <br/>
                                       <content styleCode="bold">+ Sulfonylurea</content>
                                       <br/>
                                       <content styleCode="bold">N=351</content>
                                       <br/>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone 45 mg</content>
                                       <br/>
                                       <content styleCode="bold">+ Sulfonylurea</content>
                                       <br/>
                                       <content styleCode="bold">N=351</content>
                                       <br/>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Hypoglycemia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>47 (13.4)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>55 (15.7)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Upper Respiratory Tract Infection</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>43 (12.3)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>52 (14.8)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Weight Increased</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>32 (9.1)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>47 (13.4)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Edema Lower Limb</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>20 (5.7)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>43 (12.3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Headache</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>25 (7.1)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>14 (4.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Urinary Tract Infection</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>20 (5.7)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>24 (6.8)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Diarrhea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>21 (6.0)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>15 (4.3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Nausea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>18 (5.1)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>14 (4.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>Pain in Limb</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>19 (5.4)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>14 (4.0)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In US double-blind studies, anemia was reported in ≤2% of patients treated with pioglitazone plus a sulfonylurea <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_68dff23d-b99b-4dad-9f12-a6f434544f59">5.9</linkHtml>)]</content>. 								</paragraph>
                        <paragraph>
                           <content styleCode="bold">Pioglitazone</content>
                        </paragraph>
                        <paragraph>Over 8500 patients with type 2 diabetes have been treated with pioglitazone in randomized, double-blind, controlled clinical trials, including 2605 patients with type 2 diabetes and macrovascular disease treated with pioglitazone in the PROactive clinical trial. In these trials, over 6000 patients have been treated with pioglitazone for six months or longer, over 4500 patients have been treated with pioglitazone for one year or longer, and over 3000 patients have been treated with pioglitazone for at least two years.</paragraph>
                        <paragraph>In six pooled 16- to 26-week placebo-controlled monotherapy and 16- to 24-week add-on combination therapy trials, the incidence of withdrawals due to adverse events was 4.5% for patients treated with pioglitazone and 5.8% for comparator-treated patients. The most common adverse events leading to withdrawal were related to inadequate glycemic control, although the incidence of these events was lower (1.5%) with pioglitazone than with placebo (3.0%).</paragraph>
                        <paragraph>In the PROactive trial, the incidence of withdrawals due to adverse events was 9.0% for patients treated with pioglitazone and 7.7% for placebo-treated patients. Congestive heart failure was the most common serious adverse event leading to withdrawal occurring in 1.3% of patients treated with pioglitazone and 0.6% of patients treated with placebo.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Common Adverse Events: 16- to 26-Week Monotherapy Trials:</content>
                           </content>
                        </paragraph>
                        <paragraph>A summary of the incidence and type of common adverse events reported in three pooled 16- to 26-week placebo-controlled monotherapy trials of pioglitazone is provided in <content styleCode="italics">Table 2</content>. Terms that are reported represent those that occurred at an incidence of &gt;5% and more commonly in patients treated with pioglitazone than in patients who received placebo. None of these adverse events were related to the pioglitazone dose.</paragraph>
                        <table width="100%">
                           <col width="53%"/>
                           <col width="19%"/>
                           <col width="27%"/>
                           <tbody>
                              <tr>
                                 <td colspan="3" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Table 2. Three Pooled 16- to 26-Week Placebo-Controlled Clinical Trials of Pioglitazone Monotherapy: Adverse Events Reported at an Incidence &gt;5% and More Commonly in Patients Treated with Pioglitazone than in Patients Treated with Placebo</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" colspan="3" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">% of Patients</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                       <br/>N=259</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>N=606</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Upper Respiratory Tract Infection</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>8.5</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>13.2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Headache</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>6.9</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>9.1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Sinusitis</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>4.6</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>6.3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Myalgia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>2.7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>5.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>Pharyngitis</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>0.8</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>5.1</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>A summary of the overall incidence and types of common adverse events reported in the PROactive trial is provided in <content styleCode="italics">Table 3</content>. Terms that are reported represent those that occurred at an incidence of &gt;5% and more commonly in patients treated with pioglitazone than in patients who received placebo.</paragraph>
                        <table width="100%">
                           <col width="43%"/>
                           <col width="23%"/>
                           <col width="34%"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3">Mean duration of patient follow-up was 34.5 months.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td colspan="3" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Table 3. PROactive Trial: Incidence and Types of Adverse Events Reported in &gt;5% of Patients Treated with Pioglitazone and More Commonly than Placebo</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">% of Patients</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                       <br/>N=2633</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>N=2605</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Hypoglycemia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>18.8</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>27.3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Edema</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>15.3</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>26.7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Cardiac Failure</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>6.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>8.1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Pain in Extremity</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>5.7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>6.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Back Pain</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>5.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>5.5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Chest Pain</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>5.0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>5.1</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Congestive Heart Failure</content>
                           </content>
                        </paragraph>
                        <paragraph>A summary of the incidence of adverse events related to congestive heart failure is provided in Table 4 for the 16- to 24-week add-on to sulfonylurea trials, for the 16- to 24-week add-on to insulin trials, and for the 16- to 24-week add-on to metformin trials. None of the events were fatal.</paragraph>
                        <table width="100%">
                           <col width="22%"/>
                           <col width="16%"/>
                           <col width="16%"/>
                           <col width="16%"/>
                           <col width="16%"/>
                           <col width="16%"/>
                           <tbody>
                              <tr>
                                 <td colspan="6" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Table 4. Treatment-Emergent Adverse Events of Congestive Heart Failure (CHF) </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="6" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Patients Treated with Pioglitazone or Placebo Added on to a Sulfonylurea</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="3" styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td align="center" colspan="5" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Number (%) of Patients</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" colspan="3" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Placebo-Controlled Trial</content>
                                       <br/>
                                       <content styleCode="bold">(16 weeks)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Non-Controlled</content>
                                       <br/>
                                       <content styleCode="bold">Double Blind Trial</content>
                                       <br/>
                                       <content styleCode="bold">(24 weeks)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                       <br/>
                                       <content styleCode="bold">+ Sulfonylurea</content>
                                       <br/>N=187</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>
                                       <content styleCode="bold">15 mg</content>
                                       <br/>
                                       <content styleCode="bold">+ Sulfonylurea</content>
                                       <br/>N=184</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>
                                       <content styleCode="bold">30 mg</content>
                                       <br/>
                                       <content styleCode="bold">+ Sulfonylurea</content>
                                       <br/>N=189</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>
                                       <content styleCode="bold">30 mg</content>
                                       <br/>
                                       <content styleCode="bold">+ Sulfonylurea</content>
                                       <br/>N=351</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>
                                       <content styleCode="bold">45 mg</content>
                                       <br/>
                                       <content styleCode="bold">+ Sulfonylurea</content>
                                       <br/>N=351</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>At least one congestive<br/>heart failure event</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>2 (1.1%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>1 (0.3%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>6 (1.7%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Hospitalized</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>2 (1.1%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>2 (0.6%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="6" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Patients Treated with Pioglitazone or Placebo Added on to Insulin</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="3" styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td align="center" colspan="5" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Number (%) of Patients</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" colspan="3" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Placebo-Controlled Trial</content>
                                       <br/>
                                       <content styleCode="bold">(16 weeks)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Non-Controlled</content>
                                       <br/>
                                       <content styleCode="bold">Double Blind Trial</content>
                                       <br/>
                                       <content styleCode="bold">(24 weeks)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                       <br/>
                                       <content styleCode="bold">+ Insulin</content>
                                       <br/>N=187</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>
                                       <content styleCode="bold">15 mg</content>
                                       <br/>
                                       <content styleCode="bold">+ Insulin</content>
                                       <br/>N=191</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>
                                       <content styleCode="bold">30 mg</content>
                                       <br/>
                                       <content styleCode="bold">+ Insulin</content>
                                       <br/>N=188</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>
                                       <content styleCode="bold">30 mg</content>
                                       <br/>
                                       <content styleCode="bold">+ Insulin</content>
                                       <br/>N=345</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>
                                       <content styleCode="bold">45 mg</content>
                                       <br/>
                                       <content styleCode="bold">+ Insulin</content>
                                       <br/>N=345</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>At least one congestive<br/>heart failure event</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>2 (1.0%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>2 (1.1%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>3 (0.9%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>5 (1.4%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Hospitalized</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>2 (1.0%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>1 (0.5%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>1 (0.3%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>3 (0.9%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="6" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Patients Treated with Pioglitazone or Placebo Added on to Metformin</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="3" styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td align="center" colspan="5" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Number (%) of Patients</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" colspan="3" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Placebo-Controlled Trial</content>
                                       <br/>
                                       <content styleCode="bold">(16 weeks)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Non-Controlled</content>
                                       <br/>
                                       <content styleCode="bold">Double Blind Trial</content>
                                       <br/>
                                       <content styleCode="bold">(24 weeks)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                       <br/>
                                       <content styleCode="bold">+ Metformin</content>
                                       <br/>N=160</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>
                                       <content styleCode="bold">30 mg</content>
                                       <br/>
                                       <content styleCode="bold">+ Metformin</content>
                                       <br/>N=168</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>
                                       <content styleCode="bold">30 mg</content>
                                       <br/>
                                       <content styleCode="bold">+ Metformin</content>
                                       <br/>N=411</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>
                                       <content styleCode="bold">45 mg</content>
                                       <br/>
                                       <content styleCode="bold">+ Metformin</content>
                                       <br/>N=416</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>At least one congestive<br/>heart failure event</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>1 (0.6%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>1 (0.2%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>Hospitalized</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>1 (0.6%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>1 (0.2%)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Patients with type 2 diabetes and NYHA class II or early class III congestive heart failure were randomized to receive 24 weeks of double-blind treatment with either pioglitazone at daily doses of 30 mg to 45 mg (n=262) or glyburide at daily doses of 10 mg to 15 mg (n=256). A summary of the incidence of adverse events related to congestive heart failure reported in this study is provided in Table 5.</paragraph>
                        <table width="100%">
                           <col width="63%"/>
                           <col width="20%"/>
                           <col width="17%"/>
                           <tbody>
                              <tr>
                                 <td colspan="3" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Table 5. Treatment-Emergent Adverse Events of Congestive Heart Failure (CHF) in Patients with NYHA Class II or III Congestive Heart Failure Treated with Pioglitazone or Glyburide</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Number (%) of Subjects</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>N=262</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Glyburide</content>
                                       <br/>N=256</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Death due to cardiovascular causes (adjudicated)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>5 (1.9%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>6 (2.3%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Overnight hospitalization for worsening CHF (adjudicated)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>26 (9.9%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>12 (4.7%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Emergency room visit for CHF (adjudicated)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>4 (1.5%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>3 (1.2%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>Patients experiencing CHF progression during study</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>35 (13.4%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>21 (8.2%)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Congestive heart failure events leading to hospitalization that occurred during the PROactive trial are summarized in Table 6.</paragraph>
                        <table width="100%">
                           <col width="57%"/>
                           <col width="20%"/>
                           <col width="23%"/>
                           <tbody>
                              <tr>
                                 <td colspan="3" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Table 6. Treatment-Emergent Adverse Events of Congestive Heart Failure (CHF) in PROactiveTrial</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Number (%) of Patients</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                       <br/>N=2633</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>N=2605</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>At least one hospitalized CHF event</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>108 (4.1%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>149 (5.7%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Fatal</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>22 (0.8%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>25 (1%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>Hospitalized, nonfatal</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>86 (3.3%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>124 (4.7%)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Cardiovascular Safety</content>
                           </content>
                        </paragraph>
                        <paragraph>In the PROactive trial, 5238 patients with type 2 diabetes and a history of macrovascular disease were randomized to pioglitazone (N=2605), force-titrated up to 45 mg daily or placebo (N=2633) in addition to standard of care. Almost all patients (95%) were receiving cardiovascular medications (beta blockers, ACE inhibitors, angiotensin II receptor blockers, calcium channel blockers, nitrates, diuretics, aspirin, statins, and fibrates). At baseline, patients had a mean age of 62 years, mean duration of diabetes of 9.5 years, and mean HbA1c of 8.1%. Mean duration of follow-up was 34.5 months. </paragraph>
                        <paragraph>The primary objective of this trial was to examine the effect of pioglitazone on mortality and macrovascular morbidity in patients with type 2 diabetes mellitus who were at high risk for macrovascular events. The primary efficacy variable was the time to the first occurrence of any event in a cardiovascular composite endpoint that included all-cause mortality, nonfatal myocardial infarction (MI) including silent MI, stroke, acute coronary syndrome, cardiac intervention including coronary artery bypass grafting or percutaneous intervention, major leg amputation above the ankle, and bypass surgery or revascularization in the leg. A total of 514 (19.7%) patients treated with pioglitazone and 572 (21.7%) placebo-treated patients experienced at least one event from the primary composite endpoint (hazard ratio 0.90; 95% Confidence Interval: 0.80, 1.02; p=0.10).</paragraph>
                        <paragraph>Although there was no statistically significant difference between pioglitazone and placebo for the three-year incidence of a first event within this composite, there was no increase in mortality or in total macrovascular events with pioglitazone. The number of first occurrences and total individual events contributing to the primary composite endpoint is shown in Table 7.</paragraph>
                        <table width="100%">
                           <col width="48%"/>
                           <col width="15%"/>
                           <col width="11%"/>
                           <col width="15%"/>
                           <col width="11%"/>
                           <tbody>
                              <tr>
                                 <td colspan="5" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Table 7. PROactive: Number of First and Total Events for Each Component within the Cardiovascular Composite Endpoint</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Cardiovascular Events</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                       <br/>N=2633</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>N=2605</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>First<br/>Events<br/>n (%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Total<br/>Events<br/>n</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>First<br/>Events<br/>n (%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Total<br/>Events<br/>n</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>Any event</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>572 (21.7)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>900</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>514 (19.7)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>803</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>   All-cause mortality</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>122 (4.6)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>186</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>110 (4.2)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>177</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>   Non-fatal myocardial infarction (MI)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>118 (4.5)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>157</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>105 (4.0)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>131</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>   Stroke</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>96 (3.6)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>119</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>76 (2.9)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>92</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>   Acute coronary syndrome</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>63 (2.4)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>78</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>42 (1.6)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>65</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>   Cardiac intervention (CABG/PCI)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>101 (3.8)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>240</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>101 (3.9)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>195</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>   Major leg amputation</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>15 (0.6)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>28</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>9 (0.3)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>28</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>   Leg revascularization</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>57 (2.2)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>92</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>71 (2.7)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>115</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" styleCode="Botrule " valign="middle">
                                    <paragraph>CABG = coronary artery bypass grafting; PCI = percutaneous intervention</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Weight Gain</content>
                           </content>
                        </paragraph>
                        <paragraph>Dose-related weight gain occurs when pioglitazone is used alone or in combination with other antidiabetic medications. The mechanism of weight gain is unclear but probably involves a combination of fluid retention and fat accumulation.</paragraph>
                        <paragraph>Tables 8 and 9 summarize the changes in body weight with pioglitazone and placebo in the 16- to 26-week randomized, double-blind monotherapy and 16- to 24-week combination add-on therapy trials and in the PROactive trial.</paragraph>
                        <table width="100%">
                           <col width="19%"/>
                           <col width="15%"/>
                           <col width="18%"/>
                           <col width="16%"/>
                           <col width="16%"/>
                           <col width="16%"/>
                           <tbody>
                              <tr>
                                 <td colspan="6" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Table 8. Weight Changes (kg) from Baseline during Randomized, Double-Blind Clinical Trials</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" rowspan="2" styleCode="Rrule Lrule Botrule "/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Control Group</content>
                                       <br/>
                                       <content styleCode="bold">(Placebo)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>
                                       <content styleCode="bold">15 mg</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>
                                       <content styleCode="bold">30 mg</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>
                                       <content styleCode="bold">45 mg</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Median<br/>(25<sup>th</sup>/75<sup>th</sup>
                                       <br/>percentile)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Median<br/>(25<sup>th</sup>/75<sup>th</sup>
                                       <br/>percentile)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Median<br/>(25<sup>th</sup>/75<sup>th</sup>
                                       <br/>percentile)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Median<br/>(25<sup>th</sup>/75<sup>th</sup>
                                       <br/>percentile)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Monotherapy (16 to 26 weeks)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>-1.4 (-2.7/0.0)<br/>N=256</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>0.9 (-0.5/3.4)<br/>N=79</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>1.0 (-0.9/3.4)<br/>N=188</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>2.6 (0.2/5.4)<br/>N=79</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule "/>
                                 <td styleCode="Rrule Lrule Botrule "/>
                                 <td styleCode="Rrule Lrule Botrule "/>
                                 <td styleCode="Rrule Lrule Botrule "/>
                                 <td styleCode="Rrule Lrule Botrule "/>
                                 <td styleCode="Rrule Lrule Botrule "/>
                              </tr>
                              <tr>
                                 <td align="center" rowspan="3" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Combination</content>
                                       <br/>
                                       <content styleCode="bold">Therapy</content>
                                       <br/>
                                       <content styleCode="bold">(16 to 24 weeks)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Sulfonylurea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>-0.5 (-1.8/0.7)<br/>N=187</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>2.0 (0.2/3.2)<br/>N=183</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>3.1 (1.1/5.4)<br/>N=528</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>4.1 (1.8/7.3)<br/>N=333</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Metformin</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>-1.4 (-3.2/0.3)<br/>N=160</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>N/A</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>0.9 (-1.3/3.2)<br/>N=567</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>1.8 (-0.9/5.0)<br/>N=407</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>Insulin</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>0.2 (-1.4/1.4)<br/>N=182</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>2.3 (0.5/4.3)<br/>N=190</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>3.3 (0.9/6.3)<br/>N=522</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>4.1 (1.4/6.8)<br/>N=338</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="100%">
                           <col width="51%"/>
                           <col width="24%"/>
                           <col width="25%"/>
                           <tbody>
                              <tr>
                                 <td colspan="3" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Table 9. Median Change in Body Weight in Patients Treated with Pioglitazone vs Patients Treated with Placebo During the Double-Blind Treatment Period in the PROactive Trial</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Lrule Botrule "/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Median<br/>(25<sup>th</sup>/75<sup>th</sup>
                                       <br/>percentile)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Median<br/>(25<sup>th</sup>/75<sup>th</sup>
                                       <br/>percentile)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Change from baseline to final visit (kg)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>-0.5 (-3.3, 2.0)<br/>N=2581</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>+3.6 (0.0, 7.5)<br/>N=2560</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Botrule ">
                                    <paragraph>Note: Median exposure for both Pioglitazone and Placebo was 2.7 years</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Edema</content>
                           </content>
                        </paragraph>
                        <paragraph>Edema induced from taking pioglitazone is reversible when pioglitazone is discontinued. The edema usually does not require hospitalization unless there is coexisting congestive heart failure. A summary of the frequency and types of edema adverse events occurring in clinical investigations of pioglitazone is provided in Table 10.</paragraph>
                        <table width="100%">
                           <col width="21%"/>
                           <col width="16%"/>
                           <col width="13%"/>
                           <col width="17%"/>
                           <col width="17%"/>
                           <col width="17%"/>
                           <tbody>
                              <tr>
                                 <td colspan="6" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <br/>
                                       <content styleCode="bold">Table 10. Adverse Events of Edema in Patients Treated with Pioglitazone</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" rowspan="2" styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td align="center" colspan="4" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Number (%) of Patients</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>
                                       <content styleCode="bold">15 mg</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>
                                       <content styleCode="bold">30 mg</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>
                                       <content styleCode="bold">45 mg</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Monotherapy (16 to 26 weeks)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>3 (1.2%)<br/>N=259</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>2 (2.5%)<br/>N= 81</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>13 (4.7%)<br/>N= 275</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>11 (6.5%)<br/>N=169</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle"/>
                              </tr>
                              <tr>
                                 <td align="center" rowspan="3" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Combined Therapy</content>
                                       <br/>
                                       <content styleCode="bold">(16 to 24 weeks)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Sulfonylurea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>4 (2.1%)<br/>N=187</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>3 (1.6%)<br/>N=184</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>61 (11.3%)<br/>N=540</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>81 (23.1%)<br/>N=351</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Metformin</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>4 (2.5%)<br/>N=160</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>N/A</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>34 (5.9%)<br/>N=579</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>58 (13.9%)<br/>N=416</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Insulin</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>13 (7.0%)<br/>N=187</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>24 (12.6%)<br/>N=191</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>109 (20.5%)<br/>N=533</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>90 (26.1%)<br/>N=345</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="6" styleCode="Botrule " valign="middle">
                                    <paragraph>Note: The preferred terms of edema peripheral, generalized edema, pitting edema and fluid retention were combined to form the aggregate term of "edema."</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="100%">
                           <col width="49%"/>
                           <col width="51%"/>
                           <tbody>
                              <tr>
                                 <td colspan="2" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Table 11. Adverse Events of Edema in Patients in the PROactive Trial</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Number (%) of Patients</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                       <br/>N=2633</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>N=2605</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>419 (15.9%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>712 (27.3%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode="Botrule ">
                                    <paragraph>Note: The preferred terms of edema peripheral, generalized edema, pitting edema and fluid retention were combined to form the aggregate term of "edema."</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Hepatic Effects</content>
                           </content>
                        </paragraph>
                        <paragraph>There has been no evidence of pioglitazone-induced hepatotoxicity in the pioglitazone-controlled clinical trial database to date. One randomized, double-blind, 3-year trial comparing pioglitazone to glyburide as add-on to metformin and insulin therapy was specifically designed to evaluate the incidence of serum ALT elevation to greater than three times the upper limit of the reference range, measured every eight weeks for the first 48 weeks of the trial then every 12 weeks thereafter. A total of 3/1051 (0.3%) patients treated with pioglitazone and 9/1046 (0.9%) patients treated with glyburide developed ALT values greater than three times the upper limit of the reference range. None of the patients treated with pioglitazone in the pioglitazone-controlled clinical trial database to date have had a serum ALT greater than three times the upper limit of the reference range and a corresponding total bilirubin greater than two times the upper limit of the reference range, a combination predictive of the potential for severe drug-induced liver injury.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Hypoglycemia</content>
                           </content>
                        </paragraph>
                        <paragraph>In the pioglitazone clinical trials, adverse events of hypoglycemia were reported based on clinical judgment of the investigators and did not require confirmation with fingerstick glucose testing. </paragraph>
                        <paragraph>In the 16-week add-on to sulfonylurea trial, the incidence of reported hypoglycemia was 3.7% with pioglitazone 30 mg and 0.5% with placebo. In the 16-week add-on to insulin trial, the incidence of reported hypoglycemia was 7.9% with pioglitazone 15 mg, 15.4% with pioglitazone 30 mg, and 4.8% with placebo.</paragraph>
                        <paragraph>The incidence of reported hypoglycemia was higher with pioglitazone 45 mg compared to pioglitazone 30 mg in both the 24-week add-on to sulfonylurea trial (15.7% versus 13.4%) and in the 24-week add-on to insulin trial (47.8% versus 43.5%).</paragraph>
                        <paragraph>Three patients in these four trials were hospitalized due to hypoglycemia. All three patients were receiving pioglitazone 30 mg (0.9%) in the 24-week add-on to insulin trial. An additional 14 patients reported severe hypoglycemia (defined as causing considerable interference with patient's usual activities) that did not require hospitalization. These patients were receiving pioglitazone 45 mg in combination with sulfonylurea (N=2) or pioglitazone 30 mg or 45 mg in combination with insulin (N=12).</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Urinary Bladder Tumors</content>
                           </content>
                        </paragraph>
                        <paragraph>Tumors were observed in the urinary bladder of male rats in the two-year carcinogenicity study <content styleCode="italics">[see Nonclinical Toxicology <linkHtml href="#ID_940c289c-9f6e-455c-a221-e290f34bd3a4">(13.1)</linkHtml>]</content>.  During the three year PROactive clinical trial, 14 patients out of 2605 (0.54%) randomized to pioglitazone and 5 out of 2633 (0.19%) randomized to placebo were diagnosed with bladder cancer. After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of bladder cancer, there were 6 (0.23%) cases on pioglitazone and two (0.08%) cases on placebo. After completion of the trial, a large subset of patients was observed for up to 10 additional years, with little additional exposure to pioglitazone. During the 13 years of both PROactive and observational follow-up, the occurrence of bladder cancer did not differ between patients randomized to pioglitazone or placebo (HR =1.00; 95% CI: 0.59-1.72) <content styleCode="italics">[see <linkHtml href="#ID_2db7c10b-65e8-4bf1-b77a-50013093b448">Warnings and Precautions (5.6)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Glimepiride</content>
                        </paragraph>
                        <paragraph>Adverse events that occurred in controlled clinical trials with placebo and glimepiride monotherapy, other than hypoglycemia, included: headache (7.8% and 8.2%), accidental injury (3.4% and 5.8%), flu syndrome (4.4% and 5.4%), nausea (3.4% and 5.0%) and dizziness (2.4% and 5.0%), respectively.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Hypoglycemia</content>
                           </content>
                        </paragraph>
                        <paragraph>In a randomized, double-blind, placebo-controlled monotherapy trial of 14 weeks duration, patients already on sulfonylurea therapy underwent a 3-week washout period then were randomized to glimepiride 1 mg, 4 mg, 8 mg or placebo. Patients randomized to glimepiride 4 mg or 8 mg underwent forced-titration from an initial dose of 1 mg to these final doses, as tolerated. The overall incidence of possible hypoglycemia (defined by the presence of at least one symptom that the investigator believed might be related to hypoglycemia; a concurrent glucose measurement was not required) was 4% for glimepiride 1 mg, 17% for glimepiride 4 mg, 16% for glimepiride 8 mg and 0% for placebo. All of these events were self-treated.</paragraph>
                        <paragraph>In a randomized, double-blind, placebo-controlled monotherapy trial of 22 weeks duration, patients received a starting dose of either 1 mg glimepiride or placebo daily. The dose of glimepiride was titrated to a target fasting plasma glucose of 90 −150 mg/dL. Final daily doses of glimepiride were 1, 2, 3, 4, 6 or 8 mg. The overall incidence of possible hypoglycemia (as defined above for the 14-week trial) for glimepiride versus placebo was 19.7% vs. 3.2%. All of these events were self-treated.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Weight Gain</content>
                           </content>
                        </paragraph>
                        <paragraph>Glimepiride, like all sulfonylureas, can cause weight gain.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Allergic Reactions</content>
                           </content>
                        </paragraph>
                        <paragraph>In clinical trials, allergic reactions, such as pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions, occurred in less than 1% of glimepiride-treated patients. These may resolve despite continued treatment with glimepiride. There are postmarketing reports of more serious allergic reactions (e.g., dyspnea, hypotension, shock) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_663ce6b7-5b98-4c22-b86c-1a44498ebf81">5.3</linkHtml>)]</content>. 								</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Laboratory Tests</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Elevated Serum Alanine Aminotransferase (ALT)</content>
                           </content>
                        </paragraph>
                        <paragraph>In 11 pooled placebo-controlled trials of glimepiride, 1.9% of glimepiride-treated patients and 0.8% of placebo-treated patients developed serum ALT greater than two times the upper limit of the reference range.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Laboratory Abnormalities</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Pioglitazone</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Hematologic Effects</content>
                           </content>
                        </paragraph>
                        <paragraph>Pioglitazone may cause decreases in hemoglobin and hematocrit. In placebo-controlled monotherapy trials, mean hemoglobin values declined by 2% to 4% in patients treated with pioglitazone compared with a mean change in hemoglobin of -1% to +1% in placebo-treated patients. These changes primarily occurred within the first 4 to 12 weeks of therapy and remained relatively constant thereafter. These changes may be related to increased plasma volume associated with pioglitazone therapy and are not likely to be associated with any clinically significant hematologic effects.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Creatine Phosphokinase</content>
                           </content>
                        </paragraph>
                        <paragraph>During protocol-specified measurement of serum creatine phosphokinase (CPK) in pioglitazone clinical trials, an isolated elevation in CPK to greater than 10 times the upper limit of the reference range was noted in nine (0.2%) patients treated with pioglitazone (values of 2150 to 11400 IU/L) and in no comparator-treated patients. Six of these nine patients continued to receive pioglitazone, two patients were noted to have the CPK elevation on the last day of dosing and one patient discontinued pioglitazone due to the elevation. These elevations resolved without any apparent clinical sequelae. The relationship of these events to pioglitazone therapy is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_bad75148-3d9e-416a-8df9-a335906706ba">
                     <id root="2c617de4-d188-44c8-b985-c166f4822bce"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of pioglitazone and glimepiride. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Pioglitazone</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>New onset or worsening diabetic macular edema with decreased visual acuity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_689c304b-df44-4f4e-88f1-bba619e6272e">5.10</linkHtml>)]</content>. 									</item>
                           <item>
                              <caption>•</caption>Fatal and nonfatal hepatic failure <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_53794fa4-8315-403d-bb0f-afe3fa0643e8">5.5</linkHtml>)]</content>. 									</item>
                        </list>
                        <paragraph>Postmarketing reports of congestive heart failure have been reported in patients treated with pioglitazone, both with and without previously known heart disease and both with and without concomitant insulin administration. </paragraph>
                        <paragraph>In postmarketing experience, there have been reports of unusually rapid increases in weight and increases in excess of that generally observed in clinical trials. Patients who experience such increases should be assessed for fluid accumulation and volume-related events such as excessive edema and congestive heart failure <content styleCode="italics">[see Boxed Warning</content> and <content styleCode="italics">Warnings and Precautions (<linkHtml href="#ID_43d57886-ef7e-432b-98da-4da298165ad3">5.1</linkHtml>)]</content>. 								</paragraph>
                        <paragraph>
                           <content styleCode="bold">Glimepiride</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Serious hypersensitivity reactions, including anaphylaxis, angioedema, and Stevens-Johnson Syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_663ce6b7-5b98-4c22-b86c-1a44498ebf81">5.3</linkHtml>)]</content>
                           </item>
                           <item>
                              <caption>•</caption>Hemolytic anemia in patients with and without G6PD deficiency <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_68dff23d-b99b-4dad-9f12-a6f434544f59">5.9</linkHtml>)]</content>
                           </item>
                           <item>
                              <caption>•</caption>Impairment of liver function (e.g. with cholestasis and jaundice), as well as hepatitis, which may progress to liver failure.</item>
                           <item>
                              <caption>•</caption>Porphyria cutanea tarda, photosensitivity reactions and allergic vasculitis</item>
                           <item>
                              <caption>•</caption>Leukopenia, agranulocytosis, aplastic anemia, and pancytopenia</item>
                           <item>
                              <caption>•</caption>Thrombocytopenia (including severe cases with platelet count less than 10,000/mcL) and thrombocytopenic purpura</item>
                           <item>
                              <caption>•</caption>Hepatic porphyria reactions and disulfiram-like reactions</item>
                           <item>
                              <caption>•</caption>Hyponatremia and syndrome of inappropriate antidiuretic hormone secretion (SIADH), most often in patients who are on other medications or who have medical conditions known to cause hyponatremia or increase release of antidiuretic hormone</item>
                        </list>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_36fb7917-6570-4e16-b273-a5ece36e4e85">
               <id root="ee8f63d1-1566-43b1-b800-841a0ba06f4e"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Strong CYP2C8 inhibitors (e.g., gemfibrozil) increase pioglitazone concentrations. Limit pioglitazone dose to 15 mg daily. (<linkHtml href="#ID_2ab15827-baf8-4e8b-8663-a03eab934860">2.3</linkHtml>, <linkHtml href="#ID_26d9e3b6-d7a9-4bf4-8120-875349f081f2">7.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>CYP2C8 inducers (e.g., rifampin) may decrease pioglitazone concentrations. (<linkHtml href="#ID_0bcba391-82a7-41c0-b581-6d36281930af">7.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Topiramate may decrease pioglitazone concentrations. (<linkHtml href="#S7.3">7.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Certain medications may affect glucose metabolism, requiring DUETACT dose adjustment and close monitoring of blood glucose (<linkHtml href="#S7.4">7.4</linkHtml>).</item>
                           <item>
                              <caption>•</caption>Miconazole: Severe hypoglycemia can occur when DUETACT and oral miconazole are used concomitantly. (<linkHtml href="#S7.5">7.5</linkHtml>)</item>
                           <item>
                              <caption>•</caption>CYP2C9 interactions: Inhibitors and inducers may affect glycemic control by altering glimepiride plasma concentrations. (<linkHtml href="#S7.6">7.6</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Colesevelam: Coadministration may reduce glimepiride absorption. DUETACT should be administered at least 4 hours prior to colesevelam. (<linkHtml href="#ID_516f2365-8931-476a-98aa-624650f5af10">2.4</linkHtml>, <linkHtml href="#S7.7">7.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_26d9e3b6-d7a9-4bf4-8120-875349f081f2">
                     <id root="b21952e8-230d-42d0-b989-734feeba48a4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Strong CYP2C8 Inhibitors</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Pioglitazone</content>
                        </paragraph>
                        <paragraph>An inhibitor of CYP2C8 (e.g., gemfibrozil) significantly increases the exposure (area under the serum concentration-time curve or AUC) and half-life (t<sub>½</sub>) of pioglitazone. Therefore, the maximum recommended dose of pioglitazone is 15 mg daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors. Since the minimum dose of pioglitazone in DUETACT exceeds 15 mg, patients taking concomitant strong CYP2C8 inhibitors should switch to individual components of DUETACT, unless the prescribing health care provider determines that the benefit of DUETACT clearly outweighs the risk of increased pioglitazone exposure <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_2ab15827-baf8-4e8b-8663-a03eab934860">2.3</linkHtml>) and Clinical Pharmacology (<linkHtml href="#ID_07099e0b-57b6-4d9f-9ef0-996ecac15370">12.3</linkHtml>)]</content>. 								</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0bcba391-82a7-41c0-b581-6d36281930af">
                     <id root="ff55d5ba-0d5b-4605-8679-163133c9761a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 CYP2C8 Inducers</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Pioglitazone</content>
                        </paragraph>
                        <paragraph>An inducer of CYP2C8 (e.g., rifampin) may significantly decrease the exposure (AUC) of pioglitazone. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with pioglitazone, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dose of 45 mg for pioglitazone <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_07099e0b-57b6-4d9f-9ef0-996ecac15370">12.3</linkHtml>)]</content>. 								</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.3">
                     <id root="eaa6761e-54ed-4b62-b124-bad4ed38404c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Topiramate</title>
                     <effectiveTime value="20250327"/>
                     <component>
                        <section>
                           <id root="bf2cd563-5b0a-4165-ba8e-b3761252add7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Pioglitazone</content>
                              </paragraph>
                              <paragraph>A decrease in the exposure of pioglitazone and its active metabolites were noted with concomitant administration of pioglitazone and topiramate <content styleCode="italics">[see <linkHtml href="#ID_07099e0b-57b6-4d9f-9ef0-996ecac15370">Clinical Pharmacology (12.3)</linkHtml>]</content>. The clinical relevance of this decrease is unknown; however, when DUETACT and topiramate are used concomitantly, monitor patients for adequate glycemic control.</paragraph>
                           </text>
                           <effectiveTime value="20250327"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S7.4">
                     <id root="cded2505-8e15-4a2e-8cb2-f5c552116476"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4 Drugs Affecting Glucose Metabolism</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Glimepiride</content>
                        </paragraph>
                        <paragraph>A number of medications affect glucose metabolism and may require DUETACT dose adjustment and particularly close monitoring for hypoglycemia or worsening glycemic control.</paragraph>
                        <paragraph>The following are examples of medications that may increase the glucose-lowering effect of sulfonylureas including glimepiride, a component of DUETACT, increasing the susceptibility to and/or intensity of hypoglycemia: oral anti-diabetic medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. When these medications are administered to a patient receiving DUETACT, monitor the patient closely for hypoglycemia. When these medications are withdrawn from a patient receiving DUETACT, monitor the patient closely for worsening glycemic control.</paragraph>
                        <paragraph>The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid. When these medications are administered to a patient receiving DUETACT, monitor the patient closely for worsening glycemic control. When these medications are withdrawn from a patient receiving DUETACT, monitor the patient closely for hypoglycemia.</paragraph>
                        <paragraph>Beta-blockers, clonidine, and reserpine may lead to either potentiation or weakening of DUETACT's glucose-lowering effect. </paragraph>
                        <paragraph>Both acute and chronic alcohol intake may potentiate or weaken the glucose-lowering action of DUETACT in an unpredictable fashion. </paragraph>
                        <paragraph>The signs of hypoglycemia may be reduced or absent in patients taking sympatholytic drugs such as beta-blockers, clonidine, guanethidine, and reserpine.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.5">
                     <id root="b6a916c5-26e7-4dc8-8386-08eab5c0744b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.5 Miconazole</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Glimepiride</content>
                        </paragraph>
                        <paragraph>A potential interaction between oral miconazole and sulfonylureas leading to severe hypoglycemia has been reported. Whether this interaction also occurs with other dosage forms of miconazole is not known.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.6">
                     <id root="662351d3-c152-4786-8147-a96d81bf0dac"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.6 CYP2C9 Interactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Glimepiride</content>
                        </paragraph>
                        <paragraph>There may be an interaction between glimepiride and inhibitors (e.g., fluconazole) and inducers (e.g., rifampin) of CYP2C9. Fluconazole may inhibit the metabolism of glimepiride, causing increased plasma concentrations of glimepiride which may lead to hypoglycemia. Rifampin may induce the metabolism of glimepiride, causing decreased plasma concentrations of glimepiride which may lead to worsening glycemic control.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.7">
                     <id root="c181ad62-9b67-46c1-9854-1dc4050f0a4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.7 Concomitant Administration of Colesevelam</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Glimepiride</content>
                        </paragraph>
                        <paragraph>Colesevelam can reduce the maximum plasma concentrations and total exposure of glimepiride when the two are coadministered. However, absorption is not reduced when glimepiride is administered four hours prior to colesevelam. Therefore, DUETACT should be administered at least four hours prior to colesevelam <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_07099e0b-57b6-4d9f-9ef0-996ecac15370">12.3</linkHtml>)]</content>. 								</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_e4d919a8-4a06-497a-8984-cda1d348fac0">
               <id root="fb8a515c-258d-4711-b605-fc47fd395859"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250327"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Females and Males of Reproductive Potential: Advise premenopausal females of the potential for an unintended pregnancy. (<linkHtml href="#S8.3">8.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Pediatrics: Not recommended for use in pediatric patients. (<linkHtml href="#ID_760ff6b4-7b0f-4085-8f48-45acbedf882d">8.4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Geriatric or renally impaired patients: At risk for hypoglycemia with DUETACT. Use caution in dose selection and titration, and monitor closely. (<linkHtml href="#ID_46e0e7dd-dca2-4434-b255-165c9f1233bb">8.5</linkHtml>, <linkHtml href="#ID_fbd0c1b9-09dc-4700-9380-2eec050d5a5f">8.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_248d5974-792e-4ead-8edb-23339bdab699">
                     <id root="803fb985-6827-4bee-8750-e035cf12b07d"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1	Pregnancy</title>
                     <effectiveTime value="20250327"/>
                     <component>
                        <section>
                           <id root="74d41514-37c1-4a52-a724-d2c809df38d8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Risk Summary</content>
                              </paragraph>
                              <paragraph>Limited data with DUETACT or pioglitazone in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. There are clinical considerations related to fetal and neonatal adverse reactions and drug discontinuation if glimepiride is used during pregnancy. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy <content styleCode="italics">[see <linkHtml href="#S8.1Clinical">Clinical Considerations</linkHtml>].</content>
                              </paragraph>
                              <paragraph>No adverse developmental effects were observed when pioglitazone was administered to pregnant rats and rabbits during organogenesis at exposures up to 5- and 35- times the 45 mg clinical dose, respectively, based on the body surface area. Administration of glimepiride to pregnant rats and rabbits during organogenesis induced maternal hypoglycemia and also increased fetal mortality at doses 50 (rats) and 0.1-times (rabbits) the 8 mg clinical dose, respectively, based on body surface area <content styleCode="italics">[see <linkHtml href="#S8.1Data">Data</linkHtml>]</content>.</paragraph>
                              <paragraph>The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a HbA1c &gt;7 and has been reported to be as high as 20-25% in women with a HbA1c &gt;10.  The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20% respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250327"/>
                        </section>
                     </component>
                     <component>
                        <section ID="S8.1Clinical">
                           <id root="a6eb1605-3fae-467a-ae1c-88ac27261bba"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250327"/>
                           <component>
                              <section>
                                 <id root="7f45f462-aadd-4116-a70a-1d2efef2eeec"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Disease-associated maternal and/or embryo/fetal risk</content>
                                    </paragraph>
                                    <paragraph>Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, still birth and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, still birth, and macrosomia related morbidity.</paragraph>
                                 </text>
                                 <effectiveTime value="20250327"/>
                              </section>
                           </component>
                           <component>
                              <section ID="S8.1Fetal">
                                 <id root="4ba05f4d-1d51-43d1-8410-46b7add9a224"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Fetal/Neonatal Adverse Reaction</content>
                                    </paragraph>
                                    <paragraph>Neonates of women with gestational diabetes, who are treated with sulfonylureas during pregnancy, may be at increased risk for neonatal intensive care unit admission, and may develop respiratory distress, hypoglycemia, birth injury, and be large for gestational age.  Prolonged severe hypoglycemia, lasting 4-10 days, has been reported in neonates born to mothers receiving a sulfonylurea at the time of delivery and has been reported with the use of agents with a prolonged half-life. Observe newborns for symptoms of hypoglycemia and respiratory distress and manage accordingly.</paragraph>
                                 </text>
                                 <effectiveTime value="20250327"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="4a26d9b1-ad08-4857-8833-51fd8302f315"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Dose adjustments during pregnancy and the postpartum period</content>
                                    </paragraph>
                                    <paragraph>Due to reports of prolonged severe hypoglycemia in neonates born to mothers receiving a sulfonylurea at the time of delivery, DUETACT should be discontinued at least two weeks before expected delivery <content styleCode="italics">[see <linkHtml href="#S8.1Fetal">Fetal/Neonatal Adverse Reaction</linkHtml>].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250327"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="S8.1Data">
                           <id root="1597e881-0e8d-44e0-8598-3010f363b08d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250327"/>
                           <component>
                              <section>
                                 <id root="5cddb8b0-6bd6-4537-a612-47dc30ca6251"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="bold">Animal Data</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250327"/>
                                 <component>
                                    <section>
                                       <id root="56271d60-aede-4d50-b85a-f2cccb2b2220"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Pioglitazone and Glimepiride</content>
                                          </paragraph>
                                          <paragraph>Animal reproduction studies were not conducted with the combined products in DUETACT. The following data are based on studies conducted with the individual components of DUETACT.</paragraph>
                                       </text>
                                       <effectiveTime value="20250327"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="ddcd8c76-d41b-4658-b63f-0d44c5850f54"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Pioglitazone</content>
                                          </paragraph>
                                          <paragraph>Pioglitazone administered to pregnant rats during organogenesis did not cause adverse developmental effects at a dose of 20 mg/kg (~5-times the 45 mg clinical dose), but delayed parturition and reduced embryofetal viability at 40 and 80 mg/kg, or ≥9-times the 45 mg clinical dose, by body surface area. In pregnant rabbits administered pioglitazone during organogenesis, no adverse developmental effects were observed at 80 mg/kg (~35-times the 45 mg clinical dose), but reduced embryofetal viability at 160 mg/kg, or ~69-times the 45 mg clinical dose, by body surface area.  When pregnant rats received pioglitazone during late gestation and lactation, delayed postnatal development, attributed to decreased body weight occurred in offspring at maternal doses of 10 mg/kg and above or ≥2 times the 45 mg clinical dose, by body surface area.  </paragraph>
                                       </text>
                                       <effectiveTime value="20250327"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="7aa332fa-90e5-4b18-a648-03414d81f6bd"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Glimepiride</content>
                                          </paragraph>
                                          <paragraph>Fetal deaths occurred in rats and rabbits administered glimepiride during the period of organogenesis at doses 50-times (rats) and 0.1-times (rabbits) the 8 mg clinical dose, based on body surface area. This fetotoxicity, observed only at doses inducing maternal hypoglycemia, is believed to be directly related to the pharmacologic (hypoglycemic) action of glimepiride and has been similarly noted with other sulfonylureas. </paragraph>
                                       </text>
                                       <effectiveTime value="20250327"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_03ed6cf2-fc2a-4b7b-9945-1e815bd9cfba">
                     <id root="7b1d16ec-1784-414c-a650-80c2a7630d39"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2	Lactation</title>
                     <effectiveTime value="20250327"/>
                     <component>
                        <section>
                           <id root="40a26363-3e5d-4b57-8bbb-67e73cfc0237"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Risk Summary</content>
                              </paragraph>
                              <paragraph>There is no information regarding the presence of pioglitazone or glimepiride in human milk, the effects on the breastfed infant, or the effects on milk production. Pioglitazone and glimepiride are present in rat milk; however, due to species-specific differences in lactation physiology, animal data may not reliably predict drug levels in human milk <content styleCode="italics">[see <linkHtml href="#S8.2Data">Data</linkHtml>].</content>
                              </paragraph>
                              <paragraph>The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for DUETACT and any potential adverse effects on the breastfed infant from DUETACT or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20250327"/>
                        </section>
                     </component>
                     <component>
                        <section ID="S8.2Data">
                           <id root="16adaec9-1c8d-445d-8c14-44af3731a84b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Data</content>
                              </paragraph>
                              <paragraph>During pre- and postnatal studies in rats, glimepiride was present in lactational milk and in serum of nursing rat pups. Offspring exposed to high levels of glimepiride during lactation developed skeletal abnormalities (shortening, thickening and bending of the humerus) during the postnatal period.</paragraph>
                           </text>
                           <effectiveTime value="20250327"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="c4317cad-8a0e-4651-ba80-eff47b8bae10"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 	Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>Discuss the potential for unintended pregnancy with premenopausal women as therapy with pioglitazone, like other thiazolidinediones, may result in ovulation in some anovulatory women.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_760ff6b4-7b0f-4085-8f48-45acbedf882d">
                     <id root="f9a37b42-cc88-4224-b8e4-18e335bb7beb"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of DUETACT in pediatric patients have not been established.</paragraph>
                        <paragraph>DUETACT is not recommended for use in pediatric patients based on adverse effects observed in adults, including fluid retention and congestive heart failure, fractures, and urinary bladder tumors <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_43d57886-ef7e-432b-98da-4da298165ad3">5.1</linkHtml>, <linkHtml href="#ID_2db7c10b-65e8-4bf1-b77a-50013093b448">5.6</linkHtml>, <linkHtml href="#ID_a900dc5c-aedc-4c59-baa6-fbe467ed26f2">5.7</linkHtml>, <linkHtml href="#ID_ba6afe77-f86c-4e04-aca1-34cae25dc8d7">5.8</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Glimepiride</content>
                        </paragraph>
                        <paragraph>The pharmacokinetics, efficacy and safety of glimepiride have been evaluated in pediatric patients with type 2 diabetes as described below. Glimepiride is not recommended in pediatric patients because of its adverse effects on body weight and hypoglycemia.</paragraph>
                        <paragraph>The pharmacokinetics of a 1 mg single dose of glimepiride was evaluated in 30 patients with type 2 diabetes (male = 7; female = 23) between ages 10 and 17 years. The mean (±SD) AUC (0-last) (339±203 ng•hr/mL), C<sub>max</sub> (102±48 ng/mL) and t<sub>1/2</sub> (3.1±1.7 hours) for glimepiride were comparable to historical data from adults (AUC (0-last) 315±96 ng•hr/mL, C<sub>max</sub> 103±34 ng/mL and t<sub>1/2</sub> 5.3±4.1 hours).</paragraph>
                        <paragraph>The safety and efficacy of glimepiride in pediatric patients was evaluated in a single-blind, 24-week trial that randomized 272 patients (8 to 17 years of age) with type 2 diabetes to glimepiride (n=135) or metformin (n=137). Both treatment-naïve patients (those treated with only diet and exercise for at least two weeks prior to randomization) and previously treated patients (those previously treated or currently treated with other oral antidiabetic medications for at least three months) were eligible to participate. Patients who were receiving oral antidiabetic agents at the time of study entry discontinued these medications before randomization without a washout period. Glimepiride was initiated at 1 mg, and then titrated up to 2, 4 or 8 mg (mean last dose 4 mg) through Week 12, targeting a self monitored fasting fingerstick blood glucose &lt;126 mg/dL. Metformin was initiated at 500 mg twice daily and titrated at Week 12 up to 1000 mg twice daily (mean last dose 1365 mg).</paragraph>
                        <paragraph>After 24 weeks, the overall mean treatment difference in HbA1c between glimepiride and metformin was 0.2%, favoring metformin (95% confidence interval -0.3% to +0.6%).</paragraph>
                        <paragraph>Based on these results, the trial did not meet its primary objective of showing a similar reduction in HbA1c with glimepiride compared to metformin.</paragraph>
                        <paragraph>The profile of adverse reactions in pediatric patients treated with glimepiride was similar to that observed in adults.</paragraph>
                        <paragraph>Hypoglycemic events documented by blood glucose values &lt;36 mg/dL were observed in 4% of pediatric patients treated with glimepiride and in 1% of pediatric patients treated with metformin. One patient in each treatment group experienced a severe hypoglycemic episode (severity was determined by the investigator based on observed signs and symptoms).</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_46e0e7dd-dca2-4434-b255-165c9f1233bb">
                     <id root="bba0e3fc-cb35-4808-a51c-da6c7fddc6a1"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>To minimize the risk of hypoglycemia, the initial dosing, dose increments, and maintenance dosage of DUETACT should be conservative. During initiation of DUETACT therapy and any subsequent dose adjustments, geriatric patients should be observed carefully for hypoglycemia.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Pioglitazone</content>
                        </paragraph>
                        <paragraph>A total of 92 patients (15.2%) treated with pioglitazone in the three pooled 16- to 26-week double-blind, placebo-controlled, monotherapy trials were ≥65 years old and two patients (0.3%) were ≥75 years old. In the two pooled 16- to 24-week add-on to sulfonylurea trials, 201 patients (18.7%) treated with pioglitazone were ≥65 years old and 19 (1.8%) were ≥75 years old. In the two pooled 16- to 24-week add-on to metformin trials, 155 patients (15.5%) treated with pioglitazone were ≥65 years old and 19 (1.9%) were ≥75 years old. In the two pooled 16- to 24-week add-on to insulin trials, 272 patients (25.4%) treated with pioglitazone were ≥65 years old and 22 (2.1%) were ≥75 years old. </paragraph>
                        <paragraph>In PROactive, 1068 patients (41.0%) treated with pioglitazone were ≥65 years old and 42 (1.6%) were ≥75 years old. </paragraph>
                        <paragraph>In pharmacokinetic studies with pioglitazone, no significant differences were observed in pharmacokinetic parameters between elderly and younger patients <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_07099e0b-57b6-4d9f-9ef0-996ecac15370">12.3</linkHtml>)]</content>. 								</paragraph>
                        <paragraph>Although clinical experiences have not identified differences in effectiveness and safety between the elderly (≥65 years) and younger patients, these conclusions are limited by small sample sizes for patients ≥75 years old. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Glimepiride</content>
                        </paragraph>
                        <paragraph>In clinical trials of glimepiride, 1053 of 3491 patients (30%) were ≥65 years of age. No overall differences in safety or effectiveness were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</paragraph>
                        <paragraph>There were no significant differences in glimepiride pharmacokinetics between patients with type 2 diabetes ≤65 years (n=49) and those &gt;65 years (n=42) <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_07099e0b-57b6-4d9f-9ef0-996ecac15370">12.3</linkHtml>)]</content>. 								</paragraph>
                        <paragraph>Glimepiride is substantially excreted by the kidney. Elderly patients are more likely to have renal impairment. In addition, hypoglycemia may be difficult to recognize in the elderly <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_d5a3f4e6-30f8-450a-a20d-99631baa2b7e">2.1</linkHtml>) and Warnings and Precautions (<linkHtml href="#ID_54fc55ff-dfa7-48fa-8b7b-4af50e1bc0c5">5.2</linkHtml>)]</content>. Use caution when initiating DUETACT and increasing the dose of DUETACT in this patient population.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_fbd0c1b9-09dc-4700-9380-2eec050d5a5f">
                     <id root="bced8dcf-4f25-484a-8d58-0b22691d4f47"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>To minimize the risk of hypoglycemia, the initial dosing, dose increments and maintenance dosage of DUETACT should be conservative. During initiation of DUETACT therapy and any subsequent dose adjustments, these patients should be observed carefully for hypoglycemia.</paragraph>
                        <paragraph>A multiple-dose titration study was conducted in 16 patients with type 2 diabetes and renal impairment using doses ranging from 1 mg to 8 mg daily for three months. Baseline creatinine clearance ranged from 10 to 60 mL/min. The pharmacokinetics of glimepiride were evaluated in the multiple-dose titration study and the results were consistent with those observed in patients enrolled in a single-dose study. In both studies, the relative total clearance of glimepiride increased when kidney function was impaired. Both studies also demonstrated that the elimination of the two major metabolites was reduced in patients with renal impairment <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_07099e0b-57b6-4d9f-9ef0-996ecac15370">12.3</linkHtml>)]</content>. 								</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_0963aa87-b4be-43ef-b17a-70a13fb2dd86">
               <id root="f7c76ee4-da03-4571-848a-c6e6a1f8a064"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Pioglitazone</content>
                  </paragraph>
                  <paragraph>During controlled clinical trials, one case of overdose with pioglitazone was reported. A male patient took 120 mg per day for four days, then 180 mg per day for seven days. The patient denied any clinical symptoms during this period.</paragraph>
                  <paragraph>In the event of overdosage, appropriate supportive treatment should be initiated according to the patient's clinical signs and symptoms.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Glimepiride</content>
                  </paragraph>
                  <paragraph>An overdosage of glimepiride, as with other sulfonylureas, can produce severe hypoglycemia. Mild episodes of hypoglycemia can be treated with oral glucose. Severe hypoglycemic reactions constitute medical emergencies requiring immediate treatment. Severe hypoglycemia with coma, seizure, or neurological impairment can be treated with glucagon or intravenous glucose. Continued observation and additional carbohydrate intake may be necessary because hypoglycemia may recur after apparent clinical recovery <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_54fc55ff-dfa7-48fa-8b7b-4af50e1bc0c5">5.2</linkHtml>)]</content>. 						</paragraph>
               </text>
               <effectiveTime value="20250327"/>
            </section>
         </component>
         <component>
            <section ID="ID_2e4bb3b2-c4b6-4ced-b37e-167756ce0107">
               <id root="e2f78c0e-763b-4abe-ad24-0136617a4e71"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>DUETACT tablets are a thiazolidinedione and a sulfonylurea combination product that contains two oral antihyperglycemic agents: pioglitazone and glimepiride. The concomitant use of pioglitazone and a sulfonylurea, the class of drugs that includes glimepiride, has been previously approved based on clinical trials in patients with type 2 diabetes inadequately controlled on a sulfonylurea. Additional efficacy and safety information about pioglitazone and glimepiride monotherapies may be found in the prescribing information for each individual drug.</paragraph>
                  <paragraph>Pioglitazone is an oral antidiabetic medication.</paragraph>
                  <paragraph>Pioglitazone [(±)-5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-] thiazolidinedione monohydrochloride contains one asymmetric carbon, and the compound is synthesized and used as the racemic mixture. The two enantiomers of pioglitazone interconvert <content styleCode="italics">in vivo</content>. No differences were found in the pharmacologic activity between the two enantiomers. The structural formula is as shown:</paragraph>
                  <renderMultiMedia ID="id2664198" referencedObject="ID_45b6d276-02b5-475d-8077-512d828a9955"/>
                  <paragraph>Pioglitazone hydrochloride is an odorless, white crystalline powder that has a molecular formula of C<sub>19</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub>S•HCl and a molecular weight of 392.90 daltons. It is soluble in <content styleCode="italics">N,N</content>‑dimethylformamide, slightly soluble in anhydrous ethanol, very slightly soluble in acetone and acetonitrile, practically insoluble in water, and insoluble in ether.</paragraph>
                  <paragraph>Glimepiride is an oral sulfonylurea chemically identified as 1-[[<content styleCode="italics">p</content>-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl]phenyl]sulfonyl]-3-(trans-4-methylcyclohexyl)-urea (C<sub>24</sub>H<sub>34</sub>N<sub>4</sub>O<sub>5</sub>S) with a molecular weight of 490.62. Glimepiride is a white to yellowish-white, crystalline, odorless to practically odorless powder and is practically insoluble in water. The structural formula is:</paragraph>
                  <renderMultiMedia ID="id2664212" referencedObject="ID_3c601bc0-d487-492a-bab7-d9139a5a30ae"/>
                  <paragraph>DUETACT is available as a tablet for oral administration containing 30 mg pioglitazone (as the base) with 2 mg glimepiride (30 mg/2 mg) or 30 mg pioglitazone (as the base) with 4 mg glimepiride (30 mg/4 mg) formulated with the following excipients: croscarmellose sodium NF, lactose monohydrate NF, magnesium stearate NF, hydroxypropyl cellulose NF, polysorbate 80 NF, and microcrystalline cellulose NF.</paragraph>
               </text>
               <effectiveTime value="20250327"/>
               <component>
                  <observationMedia ID="ID_45b6d276-02b5-475d-8077-512d828a9955">
                     <text>pio-chem structure.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="f5942e7a-f8c6-4b1a-be4f-ad47be5c954f-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_3c601bc0-d487-492a-bab7-d9139a5a30ae">
                     <text>glim-chem structure.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="f5942e7a-f8c6-4b1a-be4f-ad47be5c954f-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_06c3994e-463c-4b77-910b-dcbdcde4651d">
               <id root="4d01a1d5-fc45-4fbe-a8fb-0e1e5fedd810"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250327"/>
               <component>
                  <section ID="ID_64ae05aa-4233-4589-ad1f-a9fc14ea4c48">
                     <id root="554cbab3-e5bd-4889-93fd-b6c23c3ed01a"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>DUETACT combines 2 antihyperglycemic agents with different mechanisms of action to improve glycemic control in patients with type 2 diabetes: pioglitazone, a member of the thiazolidinedione class, and glimepiride, a member of the sulfonylurea class. Thiazolidinediones are insulin-sensitizing agents that act primarily by enhancing peripheral glucose utilization, whereas sulfonylureas are insulin secretagogues that act primarily by stimulating release of insulin from functioning pancreatic beta cells.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Pioglitazone</content>
                        </paragraph>
                        <paragraph>Pioglitazone is a thiazolidinedione that depends on the presence of insulin for its mechanism of action. Pioglitazone decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Pioglitazone is not an insulin secretagogue. Pioglitazone is an agonist for peroxisome proliferator-activated receptor-gamma (PPARγ). PPAR receptors are found in tissues important for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPARγ nuclear receptors modulates the transcription of a number of insulin responsive genes involved in the control of glucose and lipid metabolism.</paragraph>
                        <paragraph>In animal models of diabetes, pioglitazone reduces the hyperglycemia, hyperinsulinemia, and hypertriglyceridemia characteristic of insulin-resistant states such as type 2 diabetes. The metabolic changes produced by pioglitazone result in increased responsiveness of insulin-dependent tissues and are observed in numerous animal models of insulin resistance.</paragraph>
                        <paragraph>Because pioglitazone enhances the effects of circulating insulin (by decreasing insulin resistance), it does not lower blood glucose in animal models that lack endogenous insulin.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Glimepiride</content>
                        </paragraph>
                        <paragraph>Glimepiride primarily lowers blood glucose by stimulating the release of insulin from pancreatic beta cells. Sulfonylureas bind to the sulfonylurea receptor in the pancreatic beta cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_d110282a-2b27-498a-98b7-69ff57586ba1">
                     <id root="ed0bb7c4-6691-457a-b888-66aa5e461147"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Pioglitazone</content>
                        </paragraph>
                        <paragraph>Clinical studies demonstrate that pioglitazone improves insulin sensitivity in insulin-resistant patients. Pioglitazone enhances cellular responsiveness to insulin, increases insulin-dependent glucose disposal and improves hepatic sensitivity to insulin. In patients with type 2 diabetes, the decreased insulin resistance produced by pioglitazone results in lower plasma glucose concentrations, lower plasma insulin concentrations, and lower HbA1c values. In controlled clinical trials, pioglitazone had an additive effect on glycemic control when used in combination with a sulfonylurea, metformin, or insulin <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID_b4aef75b-fea1-430c-9047-d11c7e9f2955">14</linkHtml>)]</content>. 								</paragraph>
                        <paragraph>Patients with lipid abnormalities were included in clinical trials with pioglitazone. Overall, patients treated with pioglitazone had mean decreases in serum triglycerides, mean increases in HDL cholesterol, and no consistent mean changes in LDL and total cholesterol. There is no conclusive evidence of macrovascular benefit with pioglitazone <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_767da48d-455a-4cce-8526-d91825c95836">5.11</linkHtml>)</content> and <content styleCode="italics">Adverse Reactions (<linkHtml href="#ID_403e192e-afdf-4ae3-9f8c-8e1b6c5129cc">6.1</linkHtml>)]</content>. 								</paragraph>
                        <paragraph>In a 26-week, placebo-controlled, dose-ranging monotherapy study, mean serum triglycerides decreased in the 15 mg, 30 mg, and 45 mg pioglitazone dose groups compared to a mean increase in the placebo group. Mean HDL cholesterol increased to a greater extent in patients treated with pioglitazone than in the placebo-treated patients. There were no consistent differences for LDL and total cholesterol in patients treated with pioglitazone compared to placebo <content styleCode="italics">(Table 12)</content>. 								</paragraph>
                        <table width="100%">
                           <col width="47%"/>
                           <col width="10%"/>
                           <col width="14%"/>
                           <col width="14%"/>
                           <col width="14%"/>
                           <tfoot>
                              <tr>
                                 <td colspan="5">*Adjusted for baseline, pooled center, and pooled center by treatment interaction<br/>†p &lt;0.05 versus placebo</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td colspan="5" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Table 12. Lipids in a 26-Week Placebo-Controlled Monotherapy Dose-Ranging Study</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule "/>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>
                                       <content styleCode="bold">15 mg</content>
                                       <br/>
                                       <content styleCode="bold">Once</content>
                                       <br/>
                                       <content styleCode="bold">Daily</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>
                                       <content styleCode="bold">30 mg</content>
                                       <br/>
                                       <content styleCode="bold">Once</content>
                                       <br/>
                                       <content styleCode="bold">Daily</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>
                                       <content styleCode="bold">45 mg</content>
                                       <br/>
                                       <content styleCode="bold">Once</content>
                                       <br/>
                                       <content styleCode="bold">Daily</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Triglycerides (mg/dL)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>N=79</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>N=79</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>N=84</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>N=77</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Baseline (mean)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>263</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>284</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>261</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>260</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Percent change from baseline (adjusted mean*)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>4.8%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>-9.0%†</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>-9.6%†</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>-9.3%†</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">HDL Cholesterol (mg/dL)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>N=79</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>N=79</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>N=83</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>N=77</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Baseline (mean)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>42</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>40</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>41</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>41</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Percent change from baseline (adjusted mean*)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>8.1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>14.1%†</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>12.2%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>19.1%†</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">LDL Cholesterol (mg/dL)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>N=65</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>N=63</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>N=74</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>N=62</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Baseline (mean)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>139</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>132</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>136</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>127</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Percent change from baseline (adjusted mean*)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>4.8%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>7.2%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>5.2%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>6.0%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Total Cholesterol (mg/dL)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>N=79</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>N=79</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>N=84</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>N=77</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Baseline (mean)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>225</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>220</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>223</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>214</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Percent change from baseline (adjusted mean*)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>4.4%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>4.6%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>3.3%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>6.4%</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In the two other monotherapy studies (16 weeks and 24 weeks) and in combination therapy studies with sulfonylurea (16 weeks and 24 weeks), metformin (16 weeks and 24 weeks) or insulin (16 weeks and 24 weeks), the results were generally consistent with the data above.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Glimepiride</content>
                        </paragraph>
                        <paragraph>In healthy subjects, the time to reach maximal effect (minimum blood glucose concentrations) was approximately by two to three hours after single oral doses of glimepiride. The effects of HbA1C, fasting plasma glucose, and post-prandial glucose have been assessed in clinical trials.</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_07099e0b-57b6-4d9f-9ef0-996ecac15370">
                     <id root="c83f8295-f86a-4d71-b852-3aaaacb4d6a5"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Absorption and Bioavailability:</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">DUETACT</content>
                           </content>
                        </paragraph>
                        <paragraph>Bioequivalence studies were conducted following a single dose of the DUETACT 30 mg/2 mg and 30 mg/4 mg tablets and concomitant administration of pioglitazone (30 mg) and glimepiride (2 mg or 4 mg) under fasting conditions in healthy subjects.</paragraph>
                        <paragraph>Based on the area under the curve (AUC) and maximum concentration (C<sub>max</sub>) of both pioglitazone and glimepiride, DUETACT 30 mg/2 mg and 30 mg/4 mg were bioequivalent to pioglitazone 30 mg concomitantly administered with glimepiride (2 mg or 4 mg, respectively).</paragraph>
                        <paragraph>Food did not change the systemic exposures of glimepiride or pioglitazone following administration of DUETACT. The presence of food did not significantly alter the time to peak serum concentration (T<sub>max</sub>) of glimepiride or pioglitazone and C<sub>max</sub> of pioglitazone. However, for glimepiride, there was a 22% increase in C<sub>max</sub> when DUETACT was administered with food.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Pioglitazone</content>
                           </content>
                        </paragraph>
                        <paragraph>Following once-daily administration of pioglitazone, steady-state serum concentrations of both pioglitazone and its major active metabolites, M-III (keto derivative of pioglitazone) and M-IV (hydroxyl derivative of pioglitazone), are achieved within seven days. At steady-state, M-III and M-IV reach serum concentrations equal to or greater than that of pioglitazone. At steady-state, in both healthy volunteers and patients with type 2 diabetes, pioglitazone comprises approximately 30% to 50% of the peak total pioglitazone serum concentrations (pioglitazone plus active metabolites) and 20% to 25% of the total AUC.</paragraph>
                        <paragraph>C<sub>max</sub>, AUC, and trough serum concentrations (C<sub>min</sub>) for pioglitazone and M-III and M-IV, increased proportionally with administered doses of 15 mg and 30 mg per day.</paragraph>
                        <paragraph>Following oral administration of pioglitazone, T<sub>max</sub> of pioglitazone was within two hours. Food delays T<sub>max</sub> to three to four hours but does not alter the extent of absorption (AUC).</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Glimepiride</content>
                           </content>
                        </paragraph>
                        <paragraph>Studies with single oral doses of glimepiride in healthy subjects and with multiple oral doses in patients with type 2 diabetes showed peak drug concentrations (C<sub>max</sub>) two to three hours post-dose. When glimepiride was given with meals, the mean C<sub>max </sub>and AUC were decreased by 8% and 9%, respectively.</paragraph>
                        <paragraph>Glimepiride does not accumulate in serum following multiple dosing. The pharmacokinetics of glimepiride does not differ between healthy subjects and patients with type 2 diabetes. Clearance (CL/F) of glimepiride after oral administration does not change over the 1 mg to 8 mg dose range, indicating linear pharmacokinetics.</paragraph>
                        <paragraph>In healthy subjects, the intra- and inter-individual variabilities of glimepiride pharmacokinetic parameters were 15% to 23% and 24% to 29%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Distribution</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Pioglitazone</content>
                           </content>
                        </paragraph>
                        <paragraph>The mean apparent volume of distribution (Vd/F) of pioglitazone following single-dose administration is 0.63 ± 0.41 (mean ± SD) L/kg of body weight. Pioglitazone is extensively protein bound (&gt;99%) in human serum, principally to serum albumin. Pioglitazone also binds to other serum proteins, but with lower affinity. M-III and M-IV are also extensively bound (&gt;98%) to serum albumin.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Glimepiride</content>
                           </content>
                        </paragraph>
                        <paragraph>After intravenous (IV) dosing in healthy subjects, Vd/F was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min. Protein binding was greater than 99.5%.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Metabolism</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Pioglitazone</content>
                           </content>
                        </paragraph>
                        <paragraph>Pioglitazone is extensively metabolized by hydroxylation and oxidation; the metabolites also partly convert to glucuronide or sulfate conjugates. Metabolites M-III and M-IV are the major circulating active metabolites in humans.</paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro</content> data demonstrate that multiple CYP isoforms are involved in the metabolism of pioglitazone which include CYP2C8 and, to a lesser degree, CYP3A4 with additional contributions from a variety of other isoforms including the mainly extrahepatic CYP1A1. <content styleCode="italics">In vivo</content> study of pioglitazone in combination with gemfibrozil, a strong CYP2C8 inhibitor, showed that pioglitazone is a CYP2C8 substrate <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_2ab15827-baf8-4e8b-8663-a03eab934860">2.3</linkHtml>) and Drug Interactions (<linkHtml href="#ID_26d9e3b6-d7a9-4bf4-8120-875349f081f2">7.1</linkHtml>)]</content>. Urinary 6ß-hydroxycortisol/cortisol ratios measured in patients treated with pioglitazone showed that pioglitazone is not a strong CYP3A4 enzyme inducer.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Glimepiride</content>
                           </content>
                        </paragraph>
                        <paragraph>Glimepiride is completely metabolized by oxidative biotransformation after either an IV or oral dose. The major metabolites are the cyclohexyl hydroxy methyl derivative (M1) and the carboxyl derivative (M2). CYP2C9 is involved in the biotransformation of glimepiride to M1. M1 is further metabolized to M2 by one or several cytosolic enzymes. In animals, M1 possesses about one-third of the pharmacological activity of glimepiride, but it is unclear whether M1 results in clinically meaningful effects on blood glucose in humans. M2 is inactive.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Excretion and Elimination</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Pioglitazone</content>
                           </content>
                        </paragraph>
                        <paragraph>Following oral administration, approximately 15% to 30% of the pioglitazone dose is recovered in the urine. Renal elimination of pioglitazone is negligible and the drug is excreted primarily as metabolites and their conjugates. It is presumed that most of the oral dose is excreted into the bile either unchanged or as metabolites and eliminated in the feces.</paragraph>
                        <paragraph>The mean serum half-life (t<sub>1/2</sub>) of pioglitazone and its metabolites (M-III and M-IV) range from three to seven hours and 16 to 24 hours, respectively. Pioglitazone has an apparent clearance, CL/F, calculated to be five to seven L/hr.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Glimepiride</content>
                           </content>
                        </paragraph>
                        <paragraph>When <sup>14</sup>C-glimepiride was given orally to three healthy male subjects, approximately 60% of the total radioactivity was recovered in the urine in seven days. M1 and M2 accounted for 80% to 90% of the radioactivity recovered in the urine. The ratio of M1 to M2 in the urine was approximately 3:2 in two subjects and 4:1 in one subject. Approximately 40% of the total radioactivity was recovered in feces. M1 and M2 accounted for approximately 70% (ratio of M1 to M2 was 1:3) of the radioactivity recovered in feces. No parent drug was recovered from urine or feces. After IV dosing in patients, no significant biliary excretion of glimepiride or its M1 metabolite was observed. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Renal Impairment</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Pioglitazone</content>
                           </content>
                        </paragraph>
                        <paragraph>The serum elimination half-life of pioglitazone, M-III, and M-IV remains unchanged in patients with moderate [creatinine clearance (CLcr) 30 to 50 mL/min] and severe (CLcr &lt;30 mL/min) renal impairment when compared to subjects with normal renal function. Therefore, no dose adjustment in patients with renal impairment is required.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Glimepiride</content>
                           </content>
                        </paragraph>
                        <paragraph>In a single-dose, open-label study glimepiride 3 mg was administered to patients with mild, moderate and severe renal impairment as estimated by CLcr: Group I consisted of five patients with mild renal impairment (CLcr &gt;50 mL/min), Group II consisted of 3 patients with moderate renal impairment (CLcr = 20 to 50 mL/min) and Group III consisted of seven patients with severe renal impairment (CLcr &lt;20 mL/min). Although, glimepiride serum concentrations decreased with decreasing renal function, Group III had a 2.3-fold higher mean AUC for M1 and an 8.6-fold higher mean AUC for M2 compared to corresponding mean AUCs in Group I. The t<sub>½</sub> for glimepiride did not change, while the t<sub>½</sub> for M1 and M2 increased as renal function decreased. Mean urinary excretion of M1 plus M2 as a percentage of dose decreased from 44.4% for Group I to 21.9% for Group II and 9.3% for Group III.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Pioglitazone</content>
                           </content>
                        </paragraph>
                        <paragraph>Compared with healthy controls, subjects with impaired hepatic function (Child-Turcotte-Pugh Grade B/C) have an approximate 45% reduction in pioglitazone and total pioglitazone (pioglitazone, M-III, and M-IV) mean C<sub>max</sub> but no change in the mean AUC values. Therefore, no dose adjustment in patients with hepatic impairment is required.</paragraph>
                        <paragraph>There are postmarketing reports of liver failure with pioglitazone and clinical trials have generally excluded patients with serum ALT &gt;2.5 times the upper limit of the reference range. Use DUETACT with caution in patients with liver disease <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_53794fa4-8315-403d-bb0f-afe3fa0643e8">5.5</linkHtml>)]</content>. 								</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Glimepiride</content>
                           </content>
                        </paragraph>
                        <paragraph>It is unknown whether there is an effect of hepatic impairment on glimepiride pharmacokinetics because the pharmacokinetics of glimepiride has not been adequately evaluated in patients with hepatic impairment.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Geriatric Patients</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Pioglitazone</content>
                           </content>
                        </paragraph>
                        <paragraph>In healthy elderly subjects, C<sub>max</sub> of pioglitazone was not significantly different, but AUC values were approximately 21% higher than those achieved in younger subjects. The mean t<sub>½</sub> of pioglitazone was also prolonged in elderly subjects (about 10 hours) as compared to younger subjects (about seven hours). These changes were not of a magnitude that would be considered clinically relevant.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Glimepiride</content>
                           </content>
                        </paragraph>
                        <paragraph>A comparison of glimepiride pharmacokinetics in patients with type 2 diabetes ≤65 years and those &gt;65 years was evaluated in a multiple-dose study using 6 mg daily dose. There were no significant differences in glimepiride pharmacokinetics between the two age groups. The mean AUC at steady state for the older patients was approximately 13% lower than that for the younger patients; the mean weight-adjusted clearance for the older patients was approximately 11% higher than that for the younger patients.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Pediatric Patients</content>
                        </paragraph>
                        <paragraph>No pharmacokinetic studies of DUETACT were performed in pediatric patients.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Pioglitazone</content>
                           </content>
                        </paragraph>
                        <paragraph>Safety and efficacy of pioglitazone in pediatric patients have not been established. DUETACT is not recommended for use in pediatric patients <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_760ff6b4-7b0f-4085-8f48-45acbedf882d">8.4</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Gender</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Pioglitazone</content>
                           </content>
                        </paragraph>
                        <paragraph>The mean C<sub>max</sub> and AUC values of pioglitazone were increased 20% to 60% in women compared to men. In controlled clinical trials, HbA1c decreases from baseline were generally greater for females than for males (average mean difference in HbA1c 0.5%). Because therapy should be individualized for each patient to achieve glycemic control, no dose adjustment is recommended based on gender alone.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Glimepiride</content>
                           </content>
                        </paragraph>
                        <paragraph>There were no differences between males and females in the pharmacokinetics of glimepiride when adjustment was made for differences in body weight.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Ethnicity</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Pioglitazone</content>
                           </content>
                        </paragraph>
                        <paragraph>Pharmacokinetic data among various ethnic groups are not available.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Glimepiride</content>
                           </content>
                        </paragraph>
                        <paragraph>No studies have been conducted to assess the effects of race on glimepiride pharmacokinetics but in placebo-controlled trials of glimepiride in patients with type 2 diabetes, the reduction in HbA1c was comparable in Caucasians (n=536), blacks (n=63), and Hispanics (n=63).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Obese Patients</content>
                        </paragraph>
                        <paragraph>The pharmacokinetics of glimepiride and its metabolites were measured in a single-dose study involving 28 patients with type 2 diabetes who either had normal body weight or were morbidly obese. While the T<sub>max</sub>, CL/F, and Vd/F of glimepiride in the morbidly obese patients were similar to those in the normal weight group, the morbidly obese had lower C<sub>max</sub> and AUC than those of normal body weight. The mean C<sub>max</sub>, AUC<sub>0-24</sub>, AUC<sub>0-∞</sub> values of glimepiride in normal vs. morbidly obese patients were 547 ± 218 ng/mL vs. 410 ± 124 ng/mL, 3210 ± 1030 hours∙ng/mL vs. 2820 ± 1110 hours∙ng/mL and 4000 ± 1320 hours∙ng/mL versus 3280 ± 1360 hours∙ng/mL, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Drug-Drug Interactions</content>
                        </paragraph>
                        <paragraph>Coadministration of pioglitazone (45 mg) and a sulfonylurea (5 mg glipizide) administered orally once daily for seven days did not alter the steady-state pharmacokinetics of glipizide. Glimepiride and glipizide have similar metabolic pathways and are mediated by CYP2C9; therefore, drug-drug interaction between pioglitazone and glimepiride is considered unlikely. Specific pharmacokinetic drug interaction studies with DUETACT have not been performed, although such studies have been conducted with the individual pioglitazone and glimepiride components.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Pioglitazone</content>
                        </paragraph>
                        <table width="100%">
                           <col width="18%"/>
                           <col width="39%"/>
                           <col width="13%"/>
                           <col width="8%"/>
                           <col width="13%"/>
                           <col width="8%"/>
                           <tfoot>
                              <tr>
                                 <td colspan="6">*Daily for 7 days unless otherwise noted<br/>†% change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively<br/>‡Pioglitazone had no clinically significant effect on prothrombin time</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td colspan="6" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Table 13. Effect of Pioglitazone Coadministration on Systemic Exposure of Other Drugs </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle"/>
                                 <td align="center" colspan="5" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Coadministered Drug</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Pioglitazone</content>
                                       <br/>
                                       <content styleCode="bold">Dosage</content>
                                       <br/>
                                       <content styleCode="bold">Regimen (mg)*</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Name and Dose Regimens</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Change</content>
                                       <br/>
                                       <content styleCode="bold">in AUC†</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Change</content>
                                       <br/>
                                       <content styleCode="bold">in C<sub>max</sub>†</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" rowspan="3" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>45 mg<br/>(N=12)</paragraph>
                                 </td>
                                 <td colspan="5" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Warfarin‡</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>Daily loading then maintenance doses<br/>based PT and INR values<br/>Quick's Value = 35 ± 5%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>R-Warfarin</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↓3%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>R-Warfarin</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↓2%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>S-Warfarin</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↓1%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>S-Warfarin</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↑1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>45 mg<br/>(N=12)</paragraph>
                                 </td>
                                 <td colspan="5" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Digoxin</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>0.250 mg twice daily (loading dose) then<br/>0.250 mg daily (maintenance dose, 7 days)</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↑15%</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↑17%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" rowspan="3" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>45 mg daily<br/>for 21 days<br/>(N=35)</paragraph>
                                 </td>
                                 <td colspan="5" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Oral Contraceptive </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>[Ethinyl Estradiol (EE) 0.035 mg plus<br/>Norethindrone (NE) 1 mg] for 21 days</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>EE</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↓11%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>EE</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↓13%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>NE</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↑3%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>NE</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↓7%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>45 mg<br/>(N=23)</paragraph>
                                 </td>
                                 <td colspan="5" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Fexofenadine</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>60 mg twice daily for 7 days</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↑30%</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↑37%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>45 mg<br/>(N=14)</paragraph>
                                 </td>
                                 <td colspan="5" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Glipizide</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>5 mg daily for 7 days</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↓3%</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↓8%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>45 mg daily<br/>for 8 days<br/>(N=16)</paragraph>
                                 </td>
                                 <td colspan="5" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Metformin</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>1000 mg single dose on Day 8</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↓3%</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↓5%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>45 mg<br/>(N=21)</paragraph>
                                 </td>
                                 <td colspan="5" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Midazolam</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>7.5 mg single dose on Day 15</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↓26%</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↓26%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>45 mg<br/>(N=24)</paragraph>
                                 </td>
                                 <td colspan="5" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Ranitidine</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>150 mg twice daily for 7 days</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↑1%</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↓1%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>45 mg daily<br/>for 4 days<br/>(N=24)</paragraph>
                                 </td>
                                 <td colspan="5" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Nifedipine ER</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>30 mg daily for 4 days</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↓13%</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↓17%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>45 mg<br/>(N=25)</paragraph>
                                 </td>
                                 <td colspan="5" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Atorvastatin Ca</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>80 mg daily for 7 days</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↓14%</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↓23%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>45 mg<br/>(N=22)</paragraph>
                                 </td>
                                 <td colspan="5" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Theophylline</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>400 mg twice daily for 7 days</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↑2%</paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>↑5%</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="75%">
                           <caption>Table 14. Effect of Coadministered Drugs on Pioglitazone Systemic Exposure</caption>
                           <col width="40%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <col width="20%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule" rowspan="2">Coadministered Drug and Dosage Regimen</th>
                                 <th styleCode="Lrule Rrule Botrule" colspan="3" align="center" valign="top">Pioglitazone</th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule">Dose Regimen<br/>(mg)<footnote ID="f1">Daily for 7 days unless otherwise noted</footnote>
                                 </th>
                                 <th styleCode="Rrule">Change in AUC<footnote ID="f2">Mean ratio (with/without coadministered drug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively</footnote>
                                 </th>
                                 <th styleCode="Rrule">Change in C<sub>max</sub>
                                    <footnoteRef IDREF="f2"/>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Gemfibrozil 600 mg<br/>twice daily for 2 days<br/>(N=12)</td>
                                 <td styleCode="Rrule">15 mg single dose</td>
                                 <td styleCode="Rrule">↑3.2-fold<footnote ID="f3">The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_2ab15827-baf8-4e8b-8663-a03eab934860">2.3</linkHtml>)</content> and <content styleCode="italics">Drug Interactions (<linkHtml href="#ID_36fb7917-6570-4e16-b273-a5ece36e4e85">7</linkHtml>)]</content>
                                    </footnote>
                                 </td>
                                 <td styleCode="Rrule">↑6%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Ketoconazole 200 mg<br/>twice daily for 7 days<br/>(N=28)</td>
                                 <td styleCode="Rrule">45 mg </td>
                                 <td styleCode="Rrule">↑34%</td>
                                 <td styleCode="Rrule">↑14%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Rifampin 600 mg<br/>daily for 5 days<br/>(N=10)</td>
                                 <td styleCode="Rrule">30 mg single dose</td>
                                 <td styleCode="Rrule">↓54%</td>
                                 <td styleCode="Rrule">↓5%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Fexofenadine 60 mg<br/>twice daily for 7 days<br/>(N=23)</td>
                                 <td styleCode="Rrule">45 mg</td>
                                 <td styleCode="Rrule">↑ 1%</td>
                                 <td styleCode="Rrule">0%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Ranitidine 150 mg<br/>twice daily for 4 days<br/>(N=23)</td>
                                 <td styleCode="Rrule">45 mg</td>
                                 <td styleCode="Rrule">↓ 13%</td>
                                 <td styleCode="Rrule">↓16%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Nifedipine ER 30 mg<br/>daily for 7 days<br/>(N=23)</td>
                                 <td styleCode="Rrule">45 mg </td>
                                 <td styleCode="Rrule">↑5%</td>
                                 <td styleCode="Rrule">↑4%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Atorvastatin Ca 80 mg<br/>daily for 7 days<br/>(N = 24)</td>
                                 <td styleCode="Rrule">45 mg</td>
                                 <td styleCode="Rrule">↓24%</td>
                                 <td styleCode="Rrule">↓31%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Theophylline 400 mg<br/>twice daily for 7 days<br/>(N=22)</td>
                                 <td styleCode="Rrule">45 mg</td>
                                 <td styleCode="Rrule">↓4%</td>
                                 <td styleCode="Rrule">↓2%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Topiramate 96 mg<br/>twice daily for 7 days<footnote ID="f4">Indicates duration of concomitant administration with highest twice-daily dose of topiramate from Day 14 onwards over the 22 days of study</footnote>
                                    <br/>(N=26)</td>
                                 <td styleCode="Rrule">30 mg<footnoteRef IDREF="f4"/>
                                 </td>
                                 <td styleCode="Rrule">↓15%<footnote ID="f5">Additional decrease in active metabolites; 60% for M-III and 16% for M-IV</footnote>
                                 </td>
                                 <td styleCode="Rrule">0%</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">Glimepiride</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Aspirin</content>
                           </content>
                        </paragraph>
                        <paragraph>In a randomized, double-blind, two-period, crossover study, healthy subjects were given either placebo or aspirin 1 gram three times daily for a total treatment period of 5 days. On Day 4 of each study period, a single 1 mg dose of glimepiride was administered. The glimepiride doses were separated by a 14-day washout period. Coadministration of aspirin and glimepiride resulted in a 34% decrease in the mean glimepiride AUC and a 4% decrease in the mean glimepiride C<sub>max</sub>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Cimetidine and Ranitidine</content>
                           </content>
                        </paragraph>
                        <paragraph>In a randomized, open-label, 3-way crossover study, healthy subjects received either a single 4 mg dose of glimepiride alone, glimepiride with ranitidine (150 mg twice daily for 4 days; glimepiride was administered on Day 3), or glimepiride with cimetidine (800 mg daily for 4 days; glimepiride was administered on Day 3). Coadministration of cimetidine or ranitidine with a single 4 mg oral dose of glimepiride did not significantly alter the absorption and disposition of glimepiride.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Propranolol</content>
                           </content>
                        </paragraph>
                        <paragraph>In a randomized, double-blind, two-period, crossover study, healthy subjects were given either placebo or propranolol 40 mg three times daily for a total treatment period of five days. On Day 4 or each study period, a single 2 mg dose of glimepiride was administered. The glimepiride doses were separated by a 14-day washout period. Concomitant administration of propranolol and glimepiride significantly increased glimepiride C<sub>max</sub>, AUC, and t<sub>1/2</sub> by 23%, 22%, and 15%, respectively, and decreased glimepiride CL/F by 18%. The recovery of M1 and M2 from urine was not changed.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Warfarin</content>
                           </content>
                        </paragraph>
                        <paragraph>In an open-label, two-way, crossover study, healthy subjects received 4 mg of glimepiride daily for 10 days. Single 25 mg doses of warfarin were administered six days before starting glimepiride and on Day 4 of glimepiride administration. The concomitant administration of glimepiride did not alter the pharmacokinetics of <content styleCode="italics">R</content>- and <content styleCode="italics">S</content>-warfarin enantiomers. No changes were observed in warfarin plasma protein binding. Glimepiride resulted in a statistically significant decrease in the pharmacodynamic response to warfarin. The reductions in mean area under the prothrombin time (PT) curve and maximum PT values during glimepiride treatment were 3.3% and 9.9%, respectively, and are unlikely to be clinically relevant.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Colesevelam</content>
                           </content>
                        </paragraph>
                        <paragraph>Concomitant administration of colesevelam and glimepiride resulted in reductions in glimepiride AUC<sub>0-∞</sub> and C<sub>max</sub> of 18% and 8%, respectively. When glimepiride was administered 4 hours prior to colesevelam, there was not significant change in glimepiride AUC<sub>0-∞</sub> and C<sub>max</sub>, -6% and 3%, respectively <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_516f2365-8931-476a-98aa-624650f5af10">2.4</linkHtml>) and Drug Interactions (<linkHtml href="#S7.7">7.7</linkHtml>)]</content>. 								</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_a6a904da-8cfe-4602-b5aa-dc2f44ec7c95">
               <id root="d9abc33d-ae0e-474b-adf6-27cc191d993e"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250327"/>
               <component>
                  <section ID="ID_940c289c-9f6e-455c-a221-e290f34bd3a4">
                     <id root="7f3fea20-ad1d-4eed-acbc-4cf3ab478a43"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>No animal studies have been conducted with DUETACT. The following data are based on findings in studies performed with pioglitazone or glimepiride individually. </paragraph>
                        <paragraph>
                           <content styleCode="bold">Pioglitazone</content>
                        </paragraph>
                        <paragraph>A two-year carcinogenicity study was conducted in male and female rats at oral doses up to 63 mg/kg (approximately 14 times the maximum recommended human oral dose of 45 mg based on mg/m<sup>2</sup>). Drug-induced tumors were not observed in any organ except for the urinary bladder of male rats. Benign and/or malignant transitional cell neoplasms were observed in male rats at 4 mg/kg/day and above (approximately equal to the maximum recommended human oral dose based on mg/m<sup>2</sup>). Urinary calculi with subsequent irritation and hyperplasia were postulated as the mechanism for bladder tumors observed in male rats. A two-year mechanistic study in male rats utilizing dietary acidification to reduce calculi formation was completed in 2009. Dietary acidification decreased but did not abolish the hyperplastic changes in the bladder. The presence of calculi exacerbated the hyperplastic response to pioglitazone but was not considered the primary cause of the hyperplastic changes.</paragraph>
                        <paragraph>The relevance to humans of the bladder findings in the male rat cannot be excluded. </paragraph>
                        <paragraph>A two-year carcinogenicity study was also conducted in male and female mice at oral doses up to 100 mg/kg/day (approximately 11 times the maximum recommended human oral dose based on mg/m<sup>2</sup>). No drug-induced tumors were observed in any organ.</paragraph>
                        <paragraph>Pioglitazone hydrochloride was not mutagenic in a battery of genetic toxicology studies, including the Ames bacterial assay, a mammalian cell forward gene mutation assay (CHO/HPRT and AS52/XPRT), an <content styleCode="italics">in vitro</content> cytogenetics assay using CHL cells, an unscheduled DNA synthesis assay, and an <content styleCode="italics">in vivo</content> micronucleus assay.</paragraph>
                        <paragraph>No adverse effects upon fertility were observed in male and female rats at oral doses up to 40 mg/kg pioglitazone hydrochloride daily prior to and throughout mating and gestation (approximately nine times the maximum recommended human oral dose based on mg/m<sup>2</sup>).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Glimepiride</content>
                        </paragraph>
                        <paragraph>Studies in rats at doses of up to 5000 parts per million (ppm) in complete feed (approximately 340 times the maximum recommended human dose, based on surface area) for 30 months showed no evidence of carcinogenesis. In mice, administration of glimepiride for 24 months resulted in an increase in benign pancreatic adenoma formation that was dose-related and was thought to be the result of chronic pancreatic stimulation. No adenoma formation in mice was observed at a dose of 320 ppm in complete feed, or 46 − 54 mg/kg body weight/day. This is about 35 times the maximum human recommended dose of 8 mg once daily based on surface area.</paragraph>
                        <paragraph>Glimepiride was non-mutagenic in a battery of <content styleCode="italics">in vitro</content> and <content styleCode="italics">in vivo</content> mutagenicity studies (Ames test, somatic cell mutation, chromosomal aberration, unscheduled DNA synthesis and mouse micronucleus test).</paragraph>
                        <paragraph>There was no effect of glimepiride on male mouse fertility in animals exposed up to 2500 mg/kg body weight (&gt;1,700 times the maximum recommended human dose based on surface area). Glimepiride had no effect on the fertility of male and female rats administered up to 4000 mg/kg body weight (approximately 4,000 times the maximum recommended human dose based on surface area).</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1910a1a1-e8ad-4f1a-ba68-61957fdb4c13">
                     <id root="18962a2a-472d-425c-a445-f782b569dbd7"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Pioglitazone</content>
                        </paragraph>
                        <paragraph>Heart enlargement has been observed in mice (100 mg/kg), rats (4 mg/kg and above), and dogs (3 mg/kg) treated orally with the pioglitazone hydrochloride component of DUETACT (approximately 11, one, and two times the maximum recommended human oral dose for mice, rats, and dogs, respectively, based on mg/m<sup>2</sup>). In a one-year rat study, drug-related early death due to apparent heart dysfunction occurred at an oral dose of 160 mg/kg/day (approximately 35 times the maximum recommended human oral dose based on mg/m<sup>2</sup>). Heart enlargement was seen in a 13-week study in monkeys at oral doses of 8.9 mg/kg and above (approximately four times the maximum recommended human oral dose based on mg/m<sup>2</sup>), but not in a 52-week study at oral doses up to 32 mg/kg (approximately 13 times the maximum recommended human oral dose based on mg/m<sup>2</sup>).</paragraph>
                     </text>
                     <effectiveTime value="20250327"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_b4aef75b-fea1-430c-9047-d11c7e9f2955">
               <id root="a6a6ab27-ad8b-42a8-a8eb-b102a31a57f6"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>There have been no clinical efficacy studies conducted with DUETACT. However, the efficacy and safety of the separate components have been previously established. The coadministration of pioglitazone and a sulfonylurea, including glimepiride, has been evaluated for efficacy and safety in two clinical studies. These clinical studies established an added benefit of pioglitazone in glycemic control of patients with inadequately controlled type 2 diabetes while on sulfonylurea therapy. Bioequivalence of DUETACT with coadministered pioglitazone and glimepiride tablets was demonstrated at the 30 mg/2 mg and 30 mg/4 mg dosage strengths <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_07099e0b-57b6-4d9f-9ef0-996ecac15370">12.3</linkHtml>)]</content>. 						</paragraph>
                  <paragraph>Two clinical trials were conducted with pioglitazone in combination with a sulfonylurea. Both studies included patients with type 2 diabetes on any dose of a sulfonylurea, either alone or in combination with another antidiabetic agent. All other antidiabetic agents were withdrawn at least three weeks prior to starting study treatment.</paragraph>
                  <paragraph>In the first study, 560 patients were randomized to receive 15 mg or 30 mg of pioglitazone or placebo once daily for 16 weeks in addition to their current sulfonylurea regimen. Treatment with pioglitazone as add-on to sulfonylurea produced statistically significant improvements in HbA1c and FGP at endpoint compared to placebo add-on to sulfonylurea <content styleCode="italics">(Table 15)</content>. 						</paragraph>
                  <table width="100%">
                     <col width="53%"/>
                     <col width="14%"/>
                     <col width="17%"/>
                     <col width="17%"/>
                     <tfoot>
                        <tr>
                           <td colspan="4">*Adjusted for baseline, pooled center, and pooled center by treatment interaction<br/>†p ≤0.05 versus placebo + sulfonylurea</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td colspan="4" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Table 15. Glycemic Parameters in a 16-Week Placebo-Controlled, Add-on to Sulfonylurea Trial</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="middle"/>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Placebo</content>
                                 <br/>
                                 <content styleCode="bold">+ Sulfonylurea</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Pioglitazone 15 mg</content>
                                 <br/>
                                 <content styleCode="bold">+ Sulfonylurea</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Pioglitazone 30 mg</content>
                                 <br/>
                                 <content styleCode="bold">+ Sulfonylurea</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Total Population</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">HbA1c (%)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>N=181</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>N=176</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>N=182</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>Baseline (mean)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>9.9</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>10.0</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>9.9</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>Change from baseline (adjusted mean*)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>0.1</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>-0.8</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>-1.2</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>Difference from placebo + sulfonylurea<br/>(adjusted mean*) 95% Confidence Interval</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="middle"/>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>-0.9†<br/>(-1.2, -0.6)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>-1.3†<br/>(-1.6, -1.0)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Fasting Plasma Glucose (mg/dL)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>N=182</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>N=179</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>N=186</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>Baseline (mean)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>236</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>247</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>239</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>Change from baseline (adjusted mean*)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>6</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>-34</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>-52</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>Difference from placebo + sulfonylurea (adjusted mean*) 95% Confidence Interval</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="middle"/>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>-39†<br/>(-52, -27)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>-58†<br/>(-70, -46)</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>In the second trial, 702 patients were randomized to receive 30 mg or 45 mg of pioglitazone once daily for 24 weeks in addition to their current sulfonylurea regimen. The mean reduction from baseline at Week 24 in HbA1c was 1.6% for the 30 mg dose and 1.7% for the 45 mg dose <content styleCode="italics">(see Table 16)</content>. The mean reduction from baseline at Week 24 in FPG was 52 mg/dL for the 30 mg dose and 56 mg/dL for the 45 mg dose.</paragraph>
                  <paragraph>The therapeutic effect of pioglitazone in combination with sulfonylurea was observed in patients regardless of the sulfonylurea dose.</paragraph>
                  <table width="100%">
                     <col width="70%"/>
                     <col width="15%"/>
                     <col width="15%"/>
                     <tfoot>
                        <tr>
                           <td colspan="3">95% CI = 95% confidence interval<br/>*Adjusted for baseline, pooled center, and pooled center by treatment interaction</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td colspan="3" styleCode="Rrule Botrule Lrule Toprule ">
                              <paragraph>
                                 <br/>
                                 <content styleCode="bold">Table 16. Glycemic Parameters in a 24-Week Add-on to Sulfonylurea Trial</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule "/>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Pioglitazone</content>
                                 <br/>
                                 <content styleCode="bold">30 mg</content>
                                 <br/>
                                 <content styleCode="bold">+ Sulfonylurea</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Pioglitazone</content>
                                 <br/>
                                 <content styleCode="bold">45 mg</content>
                                 <br/>
                                 <content styleCode="bold">+ Sulfonylurea</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">Total Population</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">HbA1c (%)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>N=340</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>N=332</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule ">
                              <paragraph>Baseline (mean)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>9.8</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>9.9</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule ">
                              <paragraph>Change from baseline (adjusted mean*)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>-1.6</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>-1.7</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule ">
                              <paragraph>Difference from 30 mg daily pioglitazone + sulfonylurea (adjusted mean*) (95% CI)</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="middle"/>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>-0.1<br/>(-0.4, 0.1)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">Fasting Plasma Glucose (mg/dL)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>N=338</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>N=329</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule ">
                              <paragraph>Baseline (mean)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>214</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>217</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule ">
                              <paragraph>Change from baseline (adjusted mean*)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>-52</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>-56</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule ">
                              <paragraph>Difference from 30 mg daily pioglitazone + sulfonylurea (adjusted mean*) (95% CI)</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="middle"/>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>-5<br/>(-12, 3)</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250327"/>
            </section>
         </component>
         <component>
            <section ID="ID_5745aab0-7f40-4ec1-8358-3b9483a3f170">
               <id root="5f124584-64d8-4cf2-a8a8-26af2b63450e"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>DUETACT is available in 30 mg pioglitazone plus 2 mg glimepiride or 30 mg pioglitazone plus 4 mg glimepiride tablets as follows:</paragraph>
                  <paragraph>30 mg/2 mg tablet: white to off-white, round, convex tablets, debossed with 4833G on one side and 30/2 on the other, available in:</paragraph>
                  <paragraph>NDC 64764-302-30	Bottles of 30</paragraph>
                  <paragraph>NDC 64764-302-90	Bottles of 90</paragraph>
                  <paragraph>30 mg/4 mg tablet: white to off-white, round, convex tablets, debossed with 4833G on one side and 30/4 on the other, available in:</paragraph>
                  <paragraph>NDC 64764-304-30	Bottles of 30</paragraph>
                  <paragraph>NDC 64764-304-90	Bottles of 90</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage</content>
                  </paragraph>
                  <paragraph>Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Keep container tightly closed and protect from moisture and humidity.</paragraph>
               </text>
               <effectiveTime value="20250327"/>
            </section>
         </component>
         <component>
            <section ID="ID_418a0bfd-af83-4e14-b882-af967ecd95d4">
               <id root="921ad3cd-5e5c-421a-b8ec-152ffab33982"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>See <linkHtml href="#ID_518b7b12-e26b-4576-baf5-d7d94992d68d">FDA-approved patient labeling (Medication Guide)</linkHtml>.</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Inform patients that DUETACT is not recommended for patients with symptoms of heart failure.</item>
                     <item>
                        <caption>•</caption>Inform patients that patients with severe heart failure (NYHA Class III or IV) cannot start DUETACT as the risks exceed the benefits in such patients.</item>
                     <item>
                        <caption>•</caption>It is important to instruct patients to adhere to dietary instructions and to have blood glucose and glycosylated hemoglobin tested regularly. During periods of stress such as fever, trauma, infection, or surgery, medication requirements may change and patients should be reminded to seek medical advice promptly. Patients should also be informed of the potential risks and advantages of DUETACT and of alternative modes of therapy.</item>
                     <item>
                        <caption>•</caption>Tell patients to promptly report any sign of macroscopic hematuria or other symptoms such as dysuria or urinary urgency that develop or increase during treatment as these may be due to bladder cancer.</item>
                     <item>
                        <caption>•</caption>Prior to initiation of DUETACT therapy, the risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_54fc55ff-dfa7-48fa-8b7b-4af50e1bc0c5">5.2</linkHtml>)]</content>. Combination therapy of DUETACT with other antihyperglycemic agents may also cause hypoglycemia.</item>
                     <item>
                        <caption>•</caption>Patients who experience an unusually rapid increase in weight or edema or who develop shortness of breath or other symptoms of heart failure while on DUETACT should immediately report these symptoms to a physician.</item>
                     <item>
                        <caption>•</caption>Tell patients to promptly stop taking DUETACT and seek immediate medical advice if there is unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or dark urine as these symptoms may be due to hepatotoxicity.</item>
                     <item>
                        <caption>•</caption>Inform female patients that treatment with pioglitazone, like other thiazolidinediones may result in an unintended pregnancy in some premenopausal anovulatory females due to its effect on ovulation <content styleCode="italics">[see Use in Specific Populations <linkHtml href="#S8.3">(8.3)</linkHtml>]</content>.</item>
                     <item>
                        <caption>•</caption>Patients should be told to take a single dose of DUETACT once daily with the first main meal and instructed that any change in dosing should be made only if directed by their physician <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_6eb7db91-4594-4e9e-b287-41d9ecb8b998">2</linkHtml>)]</content>. 							</item>
                  </list>
                  <paragraph>Distributed by:<br/>
                     <content styleCode="bold">Takeda Pharmaceuticals America, Inc.</content>
                     <br/>Cambridge, MA 02142</paragraph>
                  <paragraph>DUETACT is a registered trademark of Takeda Pharmaceutical Company Limited.</paragraph>
                  <paragraph>© 2025 Takeda Pharmaceuticals America, Inc. All rights reserved. </paragraph>
                  <paragraph>DTA007 R17</paragraph>
               </text>
               <effectiveTime value="20250327"/>
            </section>
         </component>
         <component>
            <section ID="ID_518b7b12-e26b-4576-baf5-d7d94992d68d">
               <id root="eaf24560-270c-4456-bc7c-090eee91874b"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">MEDICATION GUIDE</content>
                     <br/>
                     <content styleCode="bold">DUETACT<sup>®</sup> (doo-et' -ăct)</content>
                     <br/>
                     <content styleCode="bold">(pioglitazone and glimepiride) tablets</content>
                  </paragraph>
                  <paragraph>Read this Medication Guide carefully before you start taking DUETACT and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment. If you have any questions about DUETACT, ask your doctor or pharmacist.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What is the most important information I should know about DUETACT?</content>
                     <br/>
                     <content styleCode="bold">DUETACT can cause serious side effects, including new or worse heart failure.</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Pioglitazone, one of the medicines in DUETACT, can cause your body to keep extra fluid (fluid retention), which leads to swelling (edema) and weight gain. Extra body fluid can make some heart problems worse or lead to heart failure. Heart failure means your heart does not pump blood well enough</item>
                     <item>
                        <caption>•</caption>Do not take DUETACT if you have severe heart failure</item>
                     <item>
                        <caption>•</caption>If you have heart failure with symptoms (such as shortness of breath or swelling), even if these symptoms are not severe, DUETACT may not be right for you</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Call your doctor right away if you have any of the following:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>swelling or fluid retention, especially in the ankles or legs</item>
                     <item>
                        <caption>•</caption>shortness of breath or trouble breathing, especially when you lie down</item>
                     <item>
                        <caption>•</caption>an unusually fast increase in weight</item>
                     <item>
                        <caption>•</caption>unusual tiredness</item>
                  </list>
                  <paragraph>DUETACT can have other serious side effects. See "What are the possible side effects of DUETACT?"</paragraph>
                  <paragraph>
                     <content styleCode="bold">What is DUETACT?</content>
                  </paragraph>
                  <paragraph>DUETACT is a prescription medicine used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes.</paragraph>
                  <paragraph>DUETACT contains 2 prescription diabetes medicines called pioglitazone (ACTOS<sup>®</sup>) and glimepiride, a sulfonylurea.</paragraph>
                  <paragraph>DUETACT is not for people with type 1 diabetes.</paragraph>
                  <paragraph>DUETACT is not for people with diabetic ketoacidosis (increased ketones in your blood or urine).</paragraph>
                  <paragraph>It is not known if DUETACT is safe and effective in children under the age of 18. DUETACT is not recommended for use in children.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Who should not take DUETACT?</content>
                  </paragraph>
                  <paragraph>See "What is the most important information I should know about DUETACT?"</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not take DUETACT if you:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>have severe heart failure</item>
                     <item>
                        <caption>•</caption>are allergic to any of the ingredients in DUETACT. See the end of this Medication Guide for a complete list of ingredients in DUETACT</item>
                     <item>
                        <caption>•</caption>have a condition called diabetic ketoacidosis. Diabetic ketoacidosis should be treated with insulin</item>
                  </list>
                  <paragraph>Talk to your doctor before taking DUETACT if you have any of these conditions.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What should I tell my doctor before taking DUETACT?</content>
                  </paragraph>
                  <paragraph>Before you take DUETACT, tell your doctor if you:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">have heart failure</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">have kidney problems</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">have type 1 ("juvenile") diabetes or had diabetic ketoacidosis</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">have a type of diabetic eye disease that causes swelling in the back of the eye (macular edema)</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">have liver problems</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">have or have had cancer of the bladder</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">are pregnant or plan to become pregnant.</content> It is not known if DUETACT can harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant about the best way to control your blood glucose levels while pregnant</item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">are a premenopausal woman (before the "change of life"), who does not have periods regularly or at all.</content> DUETACT may increase your chance of becoming pregnant. Talk to your doctor about birth control choices while taking DUETACT. Tell your doctor right away if you become pregnant while taking DUETACT</item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">are breastfeeding or plan to breastfeed.</content> It is not known if DUETACT passes into your milk and if it can harm your baby. Talk to your doctor about the best way to control your blood glucose levels while breastfeeding</item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">have G6PD deficiency (an inherited condition where you don't produce enough of the enzyme (G6PD).</content> Taking glimepiride, one of the medicines in DUETACT, with this condition may cause your red blood cells to be destroyed too quickly (hemolytic anemia)</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Tell your doctor about all the medicines you take</content> including prescription and over the counter medicines, vitamins, and herbal supplements.</paragraph>
                  <paragraph>DUETACT and some of your other medicines can affect each other. You may need to have your dose of DUETACT or certain other medicines changed.</paragraph>
                  <paragraph>Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist before you start a new medicine. They will tell you if it is okay to take DUETACT with other medicines.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I take DUETACT?</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Take DUETACT exactly as your doctor tells you to take it</item>
                     <item>
                        <caption>•</caption>Your doctor may change your dose of DUETACT. Do not change your dose unless your doctor tells you to</item>
                     <item>
                        <caption>•</caption>DUETACT may be prescribed alone or with other diabetes medicines. This will depend on how well your blood sugar is controlled</item>
                     <item>
                        <caption>•</caption>Take DUETACT one time each day with the first main meal</item>
                     <item>
                        <caption>•</caption>If you take colesevelam, a medicine used to lower your cholesterol, take your DUETACT at least 4 hours before you take your colesevelam.</item>
                     <item>
                        <caption>•</caption>If you miss a dose of DUETACT, take your next dose as prescribed unless your doctor tells you differently. Do not take two doses at one time the next day</item>
                     <item>
                        <caption>•</caption>If you take too much DUETACT, call your doctor or go to the nearest hospital emergency room right away</item>
                     <item>
                        <caption>•</caption>If your body is under stress such as from a fever, infection, accident, or surgery, the dose of your diabetes medicines may need to be changed. Call your doctor right away</item>
                     <item>
                        <caption>•</caption>Stay on your diet and exercise programs and test your blood sugar regularly while taking DUETACT</item>
                     <item>
                        <caption>•</caption>Your doctor should do certain blood tests before you start and while you take DUETACT</item>
                     <item>
                        <caption>•</caption>Your doctor should also do hemoglobin A1C testing to check how well your blood sugar is controlled with DUETACT</item>
                     <item>
                        <caption>•</caption>Your doctor should check your eyes regularly while you take DUETACT</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What are the possible side effects of DUETACT?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">DUETACT may cause serious side effects including:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">See "What is the most important information I should know about DUETACT?"</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">low blood sugar (hypoglycemia).</content> This can happen if you skip meals, if you also use another medicine that lowers blood sugar, or if you have certain medical problems. Lightheadedness, dizziness, shakiness, or hunger may happen if your blood sugar is too low. Severe low blood sugar can cause unconsciousness (passing out), seizures, and death. Call your doctor if low blood sugar levels are a problem for you</item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">liver problems.</content> Call your doctor right away if you have:<list listType="unordered" styleCode="Circle">
                           <item>										nausea or vomiting</item>
                           <item>										stomach pain</item>
                           <item>										unusual or unexplained tiredness</item>
                           <item>										loss of appetite</item>
                           <item>										dark urine</item>
                           <item>										yellowing of your skin or the whites of your eyes</item>
                        </list>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">bladder cancer.</content> There may be an increased chance of having bladder cancer when you take DUETACT. You should not take DUETACT if you are receiving treatment for bladder cancer. Tell your doctor right away if you have any of the following symptoms of bladder cancer:<list listType="unordered" styleCode="Circle">
                           <item>										blood or a red color in your urine</item>
                           <item>										an increased need to urinate</item>
                           <item>										pain while you urinate</item>
                        </list>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">broken bones (fractures).</content> Usually in the hand, upper arm, or foot in women. Talk to your doctor for advice on how to keep your bones healthy.</item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">diabetic eye disease with swelling in the back of the eye (macular edema). </content>Tell your doctor right away if you have any changes in your vision. Your doctor should check your eyes regularly</item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">release of an egg from an ovary in a woman (ovulation) leading to pregnancy.</content> Ovulation may happen when premenopausal women who do not have regular monthly periods take DUETACT. This can increase your chance of getting pregnant</item>
                  </list>
                  <paragraph>The most common side effects of DUETACT include:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>cold-like symptoms (upper respiratory tract infection)</item>
                     <item>
                        <caption>•</caption>headache</item>
                     <item>
                        <caption>•</caption>sinus infection</item>
                     <item>
                        <caption>•</caption>diarrhea</item>
                     <item>
                        <caption>•</caption>nausea</item>
                     <item>
                        <caption>•</caption>muscle pain</item>
                     <item>
                        <caption>•</caption>sore throat</item>
                  </list>
                  <paragraph>Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the side effects of DUETACT. For more information, ask your doctor or pharmacist.</paragraph>
                  <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I store DUETACT?</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Store DUETACT at 68°F to 77°F (20°C to 25°C). Keep DUETACT in the original container to protect from light</item>
                     <item>
                        <caption>•</caption>Keep the DUETACT bottle tightly closed and keep tablets dry</item>
                     <item>
                        <caption>•</caption>Keep DUETACT and all medicines out of the reach of children</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">General information about the safe and effective use of DUETACT</content>
                  </paragraph>
                  <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use DUETACT for a condition for which it was not prescribed. Do not give DUETACT to other people, even if they have the same symptoms you have. It may harm them.</paragraph>
                  <paragraph>This Medication Guide summarizes the most important information about DUETACT. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about DUETACT that is written for healthcare professionals. For more information, go to www.duetact.com or call 1-877-825-3327.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in DUETACT?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Active ingredients:</content> pioglitazone and glimepiride</paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactive ingredients:</content> croscarmellose sodium, lactose monohydrate, magnesium stearate, hydroxypropyl cellulose, polysorbate 80, and microcrystalline cellulose</paragraph>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Takeda Pharmaceuticals America, Inc.</content>
                  </paragraph>
                  <paragraph>Cambridge, MA 02142</paragraph>
                  <paragraph>Revised: March 2025</paragraph>
                  <paragraph>DUETACT and ACTOS are registered trademarks of Takeda Pharmaceutical Company Limited.</paragraph>
                  <paragraph>© 2025 Takeda Pharmaceuticals America, Inc. All rights reserved.</paragraph>
                  <paragraph>DTA007 R17</paragraph>
               </text>
               <effectiveTime value="20250327"/>
            </section>
         </component>
         <component>
            <section>
               <id root="fed4015b-74d4-4cc0-8fe3-1262703b70c4"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 30 mg/2 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC</content> 64764-302-30<br/>
                     <content styleCode="bold">30 Tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">duetact</content>
                     <sup>®</sup>
                     <br/>pioglitazone 30 mg and<br/>glimepiride 2 mg tablets</paragraph>
                  <paragraph>Each tablet contains pioglitazone<br/>hydrochloride equivalent to 30 mg<br/>pioglitazone and 2 mg glimepiride.</paragraph>
                  <paragraph>
                     <content styleCode="bold italics">Dispense with Medication Guide<br/>available in package insert or at<br/>www.duetact.com</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold italics">Takeda</content>
                     <br/>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <renderMultiMedia ID="id86933915" referencedObject="ID_365d3047-b55e-4af7-9fa5-b092a5b253a8"/>
               </text>
               <effectiveTime value="20250327"/>
               <component>
                  <observationMedia ID="ID_365d3047-b55e-4af7-9fa5-b092a5b253a8">
                     <text>PRINCIPAL DISPLAY PANEL - 30 mg/2 mg Tablet Bottle Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="duetact-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="b4b25704-a35a-4dd0-8448-6fa641879315"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 30 mg/4 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC</content> 64764-304-30<br/>
                     <content styleCode="bold">30 Tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">duetact</content>
                     <sup>®</sup>
                     <br/>pioglitazone 30 mg and<br/>glimepiride 4 mg tablets</paragraph>
                  <paragraph>Each tablet contains pioglitazone<br/>hydrochloride equivalent to 30 mg<br/>pioglitazone and 4 mg glimepiride.</paragraph>
                  <paragraph>
                     <content styleCode="bold italics">Dispense with Medication Guide<br/>available in package insert or at<br/>www.duetact.com</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold italics">Takeda</content>
                     <br/>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <renderMultiMedia ID="id86934806" referencedObject="E312961A-D7CF-400F-860C-78616AAAA55D"/>
               </text>
               <effectiveTime value="20250327"/>
               <component>
                  <observationMedia ID="E312961A-D7CF-400F-860C-78616AAAA55D">
                     <text>PRINCIPAL DISPLAY PANEL - 30 mg/4 mg Tablet Bottle Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="duetact-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>